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Abstract 
 
The estrogen receptors are fundamental factors in human biology. As 
transcriptional factors regulating gene programs controlling many processes in the 
body, they are key in both development and disease. Also, as nuclear receptors 
they can be activated or blocked by specific ligands, making them excellent 
targets for therapeutics. This dissertation focuses on the study of the estrogen 
receptors, both the alpha and beta isoforms (ERα and ERβ, respectively), and how 
they regulate gene transcription in human breast cancer. 
 
The proliferative role of ERα in breast cancer remains poorly understood. Here we 
show that the ion channel KCNK5 is a direct transcriptional target of ERα in 
breast cancer cell lines MCF7 and T47D. Also, we show that this is reflected by 
changes in the ion channel’s protein. Furthermore, silencing of the ion channels 
expression reduces cellular proliferation, as well as the estrogen-induction of 
proliferation. This uncovers ion channels as potential factors in the proliferation 
of breast cancer, as well as potential targets in novel treatment approaches. 
 
ERα’s role as a transcription factor has predominantly been studied in regards to 
its regulation of protein-coding genes. Herein, we show that ERα also regulates 
non-coding RNAs, such as long non-coding RNAs and pseudogenes. We also 
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potentially uncover novel protein-coding targets, by the use of novel RNA-
sequencing technology, and the use of microarrays. 
 
The other estrogen receptor, ERβ, is less characterized, but it is considered to be 
anti-proliferative in breast cancer and its activation suggested as a potential future 
therapy. However, discordant results of expression in breast tumors, correlation to 
prognosis, and tumor-suppressive function in cell lines have made this a debated 
field. We explore its role in breast cancer cells further and show that, in certain 
contexts, ERβ is not able to suppress breast cancer cell proliferation, nor, as often 
suggested, counteract ERα-mediated signaling. This warrants further studies into 
whether its activation in breast cancer is a desirable treatment. 
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1.  Introduction 
1.1 Breast cancer 
1.1.1 Epidemiology 
Breast cancer is the second most common cancer globally and among women the 
cancer with highest incident. In 2012, an estimated 1.7 million new cases were 
diagnosed, accounting for a quarter of all cancers. Furthermore, breast cancer 
ranks as the fifth cancer in terms of overall lethality, with 522,000 deaths 
annually. For female-specific cancer deaths, it is the first and second most 
common cause for death, in less and more developed regions, respectively, of the 
world (1). In the US, according to the American Cancer Society, there were 
estimated 232,340 new cases of female breast cancer and 39,620 deaths, in 2013. 
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After lung cancer, this puts breast cancer as the most frequent cause of cancer-
related death in women. A decrease in death rates has been observed since the 
late 1990s and is attributed to earlier detection, improved treatment, and possibly 
the lessened us of menopausal hormone therapy (2). Breast cancer incidence 
rates, however, remain essentially stable in the US since 2005, whereas they 
increase elsewhere (1–3). 
 
1.1.2 Etiology and pathophysiology 
The causes and development of breast cancer are still elusive. Obvious cancer-
associated factors such as heredity, obesity, and exposure to exogenous agents are 
implied, including an increased exposure to the female sex hormones, e.g. late 
menopause, early menarche, delayed childbirth or nulliparity, and hormonal 
therapy and contraceptive usage. Additionally, socioeconomic status has been 
indicated (4). Although family history is the strongest predictor of breast cancer 
after gender and age, only 5 to 10% of cases are due to known familial mutations 
(4,5). These are primarily in either of the two well-established susceptibility genes 
BRCA1 and BRCA2, although other high-penetrance breast-cancer susceptibility 
genes have been identified (such as TP53, STK11, ATM, BRIP1, CHEK2, NBN, 
RAD51C, and PTEN). This list is expected to grow as new genomic techniques are 
used to uncover the nature of human cancers (6,7). 
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Breast cancer is a highly heterogeneous disease with at least 18 different 
acknowledged histological types, of which the most common are mammary ductal 
and lobular carcinoma (8). These carcinomas develop as neoplasms from the layer 
of epithelial cells that line the lumen of the milk ducts or the lobules, respectively 
(9). The epithelial cells are enveloped by myoepithelial cells and the basement 
membrane. When confined by these layers, the carcinoma is said to be in situ. 
This is a precursor stage to invasive breast cancer, which is when the tumor 
penetrates the surrounding layers. Various genetic and epigenetic alterations, 
such as increased responsiveness to hormones and growth factor and abnormal 
expression of oncogenes and tumor-suppressor genes, can occur in the transition 
between these two states (10,11). Ductal and lobular breast carcinomas represent 
50-80% and 5-15% of breast tumors, respectively, and are therefore the most 
studied types (8,12,13). The other, so called, “special types” of breast cancer are 
associated with particular tumor characteristics, but the utility of these in 
diagnostics and treatment has not been realized due to lack of standards and 
variability in classification (14).  
 
Breast cancers are also classified according to grade and expression of biomarkers. 
The grade of a breast cancer is scored based on morphological differentiation, 
nuclear atypia, and mitotic rate. Pathologists also assess include the size, surgical 
margins, and spread axillary lymph nodes (15). Although fast and reliable in 
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determining cancers of different prognosis, the histopathology of breast cancer is 
limited in informing the choice of therapy. Hence, the trio of biomarkers 
consisting of estrogen receptor alpha (ERα), progesterone receptor (PR), and 
human epidermal growth factor receptor (HER2), is assessed by 
immunohistochemistry in the clinical setting to determine treatment approach. 
Accordingly, breast cancers are divided into ER-positive (ERα+/PR+), HER2-
positive (ERα−/HER2+), and triple negative (ERα−/PR−/HER2−) tumors. 
Patients with ER-positive tumors have the best overall outcome, followed by those 
with HER2-positive. Triple-negative tumors have the poorest average outcome 
and lack a targeted therapy (16). 
 
1.1.3 Molecular subtypes 
Aside from histological types and grade, breast cancers can also be classified 
according to molecular characteristics. Additional methods to systematically 
classify tumors do so by use of gene-expression signatures. These so called 
molecular subtypes of breast cancers, categorizes tumors according to their gene-
expression patterns into luminal A, luminal B, basal-like, HER2, and normal-
breast-like tumors. Like the histological classes, these subtypes have prognostic 
value. The luminal A and B subtypes represent both ends of the continuum made 
up of most ERα-positive tumors, with the former subtype exhibiting better 
outcome and the latter worse outcome, respectively (17–20). Conversely, the 
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basal-like subtype, which is similar to the triple-negative type, has the worst 
prognosis of all subtypes (18–20). These so called gene signatures have been 
employed in testing platforms, which so far serve supplemental roles to traditional 
histopathological methods (21). It is of note that this approach to characterizing 
breast cancer is suboptimal, emphasizing the heterogeneous nature of the disease, 
for example in showing that different histological types may have similar 
transcriptomes, yet associate with different patient prognosis (13). Among current 
efforts to extensively characterize the complexity of breast cancers is The Cancer 
Genome Atlas Network’s integrative analysis of genomic, proteomic, and 
transcriptomic data from thousands of samples to better understand the tumor 
etiology (7). Ultimately, the goal is to utilize the information gained from this 
type of tumor characterization to tailor therapy by predicting outcome and 
response to treatment (22). 
 
1.1.4 Role of estrogen 
Expression of hormone receptors in the tumor is among the most important 
biomarkers for treatment decisions and prognosis. The involvement of the 
hormone estrogen in mammary carcinogenesis was proposed in the middle of last 
century, based on finding in studies with mice (23), and was later supported by 
epidemiological findings (24). The hypothesis is that abnormal exposure to the 
hormone stimulates cellular proliferation, resulting in neoplasia. The increased 
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cell division increases the chance of somatic mutations, which lead to 
transformation and breast cancer (25). Aforementioned estrogen-associated risk 
factors also support this notion. As an alternative to the mitogenic role of estrogen 
in the development of breast cancer, there also exists a hypothesis that estrogen 
and its metabolites are genotoxic, thereby triggering neoplastic transformation 
(26).  
 
1.1.5 Available treatments 
Current treatments options for breast cancer are surgery, radiation therapy, 
chemotherapy, hormonal therapy, and targeted treatments. Adjuvant systemic 
treatment is particularly beneficial for patients at high risk of relapse. Depending 
on hormone-receptor status (see more below), these patients are candidates for 
chemotherapy or endocrine therapy. Endocrine treatment options include 
tamoxifen, aromatase inhibitors, and ovarian ablation or suppression (discussed 
below). The former two are also options for low-risk patients (27). Targeted 
therapies for tumors of certain molecular characteristic are available and also the 
forefront of pharmacological development. For HER2+ tumors, the monoclonal 
antibody trastuzumab is demonstrated to improve survival, and other agents, such 
as lapatinib, targeting the same molecular pathway are available. Clinical tests of 
agents acting on other targets are in clinical trials (28). Importantly, the different 
types of breast cancer, be it histological or molecular, represent the intertumor 
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heterogeneity of the disease and guide decisions for treatment in the clinic. 
However, the intratumor heterogeneity of breast cancer, i.e. the diversity in 
genetic and epigenetic changes between cells within one tumor, is a novel aspect 
to consider in the design of new therapeutic options (29). In certain cases it might 
be favorable to target a certain subset of tumor cells, for instances those that 
exhibit a proliferative or metastatic phenotype, instead of the bulk of the tumor. 
 
1.2 Estrogen 
1.2.1 Estrogen and its receptors 
Estrogens are produced by the aromatization of testosterone or androstenedione, 
a reaction carried out by aromatase enzymes (CYP19A1). In the premenopausal 
woman, this conversion occurs mainly in the ovaries, and estradiol (17β-estradiol, 
E2) is the estrogen of highest concentration and potency. After menopause, 
estrone (E1) is the predominant estrogen, and its sources are extragonadal sites, 
especially adipose tissue (30,31).  
 
The estrogen receptors alpha and beta (ERα and ERβ) are encoded from the genes 
ESR1 and ESR2, respectively. Both ERs are expressed and functioning in multiple 
tissues in both sexes, despite estrogen being recognized as the female sex 
hormone. Human and rodent studies have detected expression of either or both 
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ERs, at mRNA or protein levels, in a wide host of tissues, including the brain and 
spinal cord, the cardiovascular system, the urogenital tract, the skeletal system, 
the gastrointestinal tract, adipose tissue, pancreas, liver, kidney, mammary gland, 
ovary, lung, and prostate (32,33). However, the data on ER expression, in both 
normal and cancer tissue, are in some cases controversial and complex. 
Additionally, this field is hampered by technical issues and unspecific reagents 
related to detection of ERβ. 
 
1.2.2 Structure and function of the estrogen receptors 
ERα and ERβ are ligand-activated transcription factors. Their proteins possess 
similar domains but do not exhibit high sequence similarity in all (Figure 1.1). 
Notable, their zinc finger-containing DNA-binding domains (DBDs) are 96% 
similar, whereas the C-terminal ligand-binding domain (LBD) and the N-terminal 
transactivation function 1 (AF-1) are similar to 53 and 30%, respectively. A hinge 
domain connecting the LBD and DBD is 30% similar between the two ERs (34). 
These forms of ERα and ERβ measure 595 (66 kDa) and 530 amino acids (59 
kDa), respectively. Both receptors exist in other, less common, isoforms, which 
will not be discussed here. 
 
The so-called classical action of the ERs is activation through binding to estrogen. 
Despite the differences in the LDBs, ERα and ERβ bind E2 with similar affinities, 
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although this is not the case for various other natural or synthetic compounds 
(35–37). Subsequent to ligand binding, the ERs bind directly to DNA or tethers to 
other DNA-bound factors, to regulate transcription of target genes. As predicted 
by the similarity in their DBD, the receptors share many genomic binding sites, 
but also have unique target sites (38–40). The diverging AF-1 domains, the 
ligand-independent activation domain, are suggested as explanation to different, 
and sometimes opposite response, of the receptors to various ligands (41,42). 
Correspondingly, differences in interactions with coregulatory proteins are 
explained by differences in the LBD, wherein lies the ligand-dependent activation 
domain (AF-2) (42). Both ERs are active in homo- or heterodimeric complexes 
that interact with the transcriptional machinery. In addition to the classical, 
genomic, function of the ERs, there are also non-genomic, extranuclear, functions 
of the receptors, whereby they crosstalk with various kinase-signaling pathways 
(43). Furthermore, these pathways can also impinge on the nuclear actions of the 
ERs (44). A membrane-bound estrogen receptor has been described. This G 
protein-coupled estrogen receptor (GPER1) has been demonstrated to be activated 
by E2 and selective ligands, and confer cytosolic signaling through various 
pathways (45). A schematic of ER signaling pathways is shown in Figure 1.2. 
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Figure 1.1. Structure of the estrogen receptors. Percentages show amino acid sequence identity. 
The N-terminal domain (A/B) possesses the ligand-independent AF-1 domain, whereas the AF-2 
and LBD domains are C-terminal (E/F). These are connected by the DBD (C) and the hinge 
domain (D) 
 
1.2.3 Role of estrogen receptors in breast development and disease 
Estrogen is a major regulator of the postnatal development of the mammary 
gland. During this process, ducts stemming grow out to form a branched structure 
in the mammary fat pad. Pregnancy and lactation causes further structural 
changes in the mammary gland, to allow for secretion of milk. A role for ERα in 
the estrogen-controlled process is verified by the fact that ERα knock-out 
(αERKO) mice have glands akin to that of a newborn (46). The stimulation of 
glandular development by estrogen in ovariectomized mice and its inhibition by 
antiestrogens further support this notion (47,48). Unlike that of αERKO mice, the 
mammary gland of ERβ knock-out mice seems to develop and be capable of 
lactation, although there are data showing incomplete development (49–51). 
Disruption of both genes causes a phenotype similar to the αERKO phenotype 
(52). However, mammary gland development can be restored in the αERKO mice 
by pituitary grafting, suggesting that the mammogenic process is activated 
 11 
directly at the gland, as well as by endocrine signals from the pituitary gland (53). 
In mouse tumor models, lack of ERα delays or disrupts the tumorigenesis, 
although its expression, in these models, unexpectedly declines throughout tumor 
progression (54,55). 
 
 
Figure 1.2. Estrogen receptor signaling. The estrogen receptors are activated by ligand binding 
(1), which causes homo- or heterodimerization (2), followed by transcriptional modulation of 
target genes through direct (3) and indirect (4) DNA binding to cis-regulatory elements. The ERs 
can also be activated by phosphorylations, and themselves trigger kinase cascades (5). 
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ERα-positive tumors are, despite the receptors mitogenic function, associated with 
more differentiated tumors and better prognosis. However, ERα-positive breast 
cancer remain the majority of cases, its incidence, for unclear reasons, is 
increasing in the US, and it is the type responsible for most deaths (56,57).  
 
 
Figure 1.3. Estrogen receptor mRNA expression in clinical samples.  The two left panels show 
normalized mRNA expression for ERα (ESR1) and ERβ (ESR2) in human female breast tumor 
samples, stratified by molecular subtype. The two right panels similarly show expression of the 
ERs, in samples from normal and breast cancer tissue. Figure areas in violin plots represent size of 
subset and crossbars the median value. Expression values are normalized transcript count 
estimates, according to the RSEM algorithm for RNA-seq analysis (58). Data consisting of 946 and 
107 tumor and normal samples, respectively, acquired from TCGA (7). 
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The role of ERβ is more elusive, though it appears, as mainly supported by in vitro 
experiments, to be a tumors suppressor in the breast (59). Conflicting and 
confounding data exist regarding its expression and function, and a contradicting 
relationship between protein levels, as per antibody-based assays, and mRNA 
levels is often found. Compared to ERα, the mRNA levels of ERβ in tumor samples 
seem to be consistently low, even lower than levels of ERα in ERα-negative 
tumors (Figure 1.3). Nonetheless, the common finding in the most recent body of 
data from immunohistochemical studies of clinical samples is that ERβ is 
expressed in a majority of breast cancers, either as sole ER or together with ERα 
(Figure 1.4) (60–73). Mouse models also indicate this to be the case (55). 
However, studies also find that ERβ expression is decreased, but not lost, in the 
progression from normal to invasive lesions (51,59,62,74–77). The paradoxical 
relationship between ERβ’s proposed tumor-suppressor function and prevalent 
tumor expression is further complicated by its association with clinical 
parameters; there are studies correlating ERβ expression to both proliferative and 
anti-proliferative markers, possibly suggesting a variable and context-dependent 
role for ERβ (61,63,65,66,78,79). Ultimately, both ERs function may differ in 
function in the presence of the other ER, as well as in the presence of various 
coregulatory proteins. 
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Figure 1.4. Distribution of ER-protein positive tumors in studies of clinical samples. Shown is 
percentage of total study population classified as according to expression of the two ERs. Sources 
A-O (61,63,65,66,69,78,80–88). Data from K are results of analyses with different antibodies, 
accordingly: 1) C-terminal antibody, 2) N-terminal antibody, and 3) total amount. 
 
1.2.4 Targeted therapeutics 
Because of the demonstrated effect of ERα on the proliferation of breast tumors, it 
is an obvious therapeutic target. Aforementioned use of aromatase inhibitors, 
which ablate the supply of estrogen, and tamoxifen and fulvestrant, which 
antagonize ERα, are proven to improve survival (89). Nevertheless, relapse and 
treatment resistance hamper their efficacy in the long term. Almost half of ERα-
positive patients fail to respond to tamoxifen, and at least 40% of patients treated 
with adjuvant tamoxifen, and nearly all with metastatic disease, eventually 
relapse and die from the disease (90,91). The use of novel selective estrogen-
receptor modulators (SERMs), small compounds with both tissue- and receptor-
specific effects, remains a promising venue in breast cancer prevention and 
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treatment (92). Raloxifene, with an efficacy similar to tamoxifen’s but lower risk 
of side effects, is an example of the development in this field. However, as for 
other treatment alternatives, the possibility of resistance exists for SERMs as well, 
as is shown by development of raloxifene and tamoxifen resistance (93).  
 
1.2.5 Cell line models of breast cancer 
In vitro culture of human breast cancer cell lines is a commonplace model for the 
study of breast cancer biology. The first estrogen-responsive cell line, named 
MCF7, was established in the 1970s and it is now a main tool in many molecular-
biology laboratories (94). The MCF7 and T47D cells are characterized by a gene 
expression pattern indicating a luminal epithelial origin and express markers 
typical of this phenotype, such as E-cadherin and desmoplakin (95–98). They are 
also tumorigenic in mouse models and may be predictive of clinical performance 
of drugs (99). Caution should be taken when extrapolating data from breast 
cancer cell lines, however, as they, for example show higher grades of aneuploidy 
than tumor cells, exhibit more aggressive phenotypes than their origin, and 
obviously are not exposed to the tumor microenvironment (97,98,100).
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2.  Material and methods 
2.1 Reagents 
All cell culture reagents were from Life Technologies (Carlsbad, CA). 17β-
estradiol (E2), and tamoxifen were from Sigma (St. Louis, MO). ICI 182,780 
(ICI), PPT, and DPN were from Tocris Bioscience (Bristol, United Kingdom). 
KB101471 and LY3201 were gifts from KaroBio (Huddinge, Sweden) and Eli Lilly 
(Indianapolis, IN), respectively. Anti-ERα antibody HC-20, anti-ERβ antibody 
NBP1-04936, and anti-β-actin antibody AC-15 were from SantaCruz 
Biotechnology (Dallas, TX), Novus Biologicals (Littleton, CO), and Sigma, 
respectively. Secondary anti-mouse and anti-rabbit antibodies (NA931V and 
NA934V, respectively) were from GE Healthcare (Piscataway, NJ), and secondary 
anti-chicken antibody 31401 from Thermo Scientific (Rockford, IL). 
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2.2 Cell culture and ligand treatments 
Human breast cancer cell lines T47D and MCF7 were acquired from ATCC 
(Manassas, VA). T47D cells were grown in DMEM/F12 (mixed 1:1) supplemented 
with 5% heat-inactivated fetal bovine serum (FBS, Sigma) and 100 U/ml 
penicillin-100 μg/ml streptomycin (PenStrep). MCF7 cells were grown in DMEM 
supplemented with 5% heat-inactivated FBS and PenStrep. Cells were cultured in 
a humidified incubator at 37°C in 5% CO2. All cell culture experiments were 
carried out before 30 passages and with culture free from mycoplasma, as verified 
by qPCR analysis with primer pair amplifying rRNA gene from multiple 
mycoplasma species (F: 5’-TCTGAATYTGCCGGGACCACC-3’, R: 5’- 
CTTTCCMTCACKGTACTRGTTCACT-3’). 
 
T47D and MCF7 cells were synchronized before ligand treatment by incubation 
for 24 h in respective medium without phenol red supplemented with 5% 
dextran-coated charcoal-stripped FBS (DCC-FBS) and PenStrep, followed by 48 h 
incubation in medium supplemented with 0.5% DCC-FBS. After synchronization, 
cells were treated with ligands dissolved in ethanol or DMSO (with respective 
vehicle used as control), in 0.5% DCC-FBS supplemented medium. 
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2.3 Cell counting and viability assays 
Counting of cells for quantitative purpose or seeding was carried out with 
automatic cell counter Countess (Life Technologies). Trypsinized cells were mixed 
1:1 with tryphan blue before counting in two or three replicates. 
 
Cell viability was determined using the MTS assay (Celltiter 96 AQueous One 
Solution Cell Proliferation Assay, Promega, Madison, WI) following the 
manufacturer’s instructions. The assay was always run in at least triplicates and 
absorbance readings were carried out before saturation on a SpectroMax M5 
Microplate Reader (Molecular Devices, Sunnyvale, CA). 
 
2.4 RNA extraction and cDNA synthesis 
RNA was extracted from cultured cells with QIAzol (Qiagen, Germantown, MD) 
or TRIzol (Life Technologies) and purified with RNeasy Mini Kit (Qiagen), 
according to the manufacturer’s instructions, including on-column DNA digestion 
with deoxyribonuclease I (DNase I, Qiagen). For microarray and sequencing 
experiments, the RNA integrity was verified to be > 8, using a 2100 Bioanalyzer 
and application-appropriate kit (Agilent, Santa Clara, CA). For other experiments, 
the purity of extracted RNA was verified at measurement of concentration with 
NanoDrop 1000 Spectrophotometer (NanoDrop, Wilmington, DE). 
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Synthesis of cDNA was carried out in a total volume of 20 μl using 0.4–1 μg of 
RNA to which 0.1 nmol of random-hexamer primers (Integrated DNA 
Technologies, Coralville, IA) were added. The mixture was incubated for 10 min 
at 70°C and 5 min on ice after which 1× first-strand buffer, 5 mM dithiothreitol 
(both from Life Technologies), and 0.5 mM deoxynucleotide triphosphates 
(Sigma) were added. After addition of 200 U Superscript III (Life Technologies), 
the reaction was started at 25°C for 10 min, and continued at 46°C for 1 h. The 
enzyme was deactivated at 70°C for 15 min. 
 
2.5 Quantitative polymerase chain reaction 
For each qPCR, 10 ng of cDNA were used, with 1 pmol of forward and reverse 
primer and 1× Fast SYBR Green Master Mix (Life Technologies). Samples were 
run in duplicates or triplicates with no-template control on a 7500 Fast Real-Time 
PCR (Life Technologies). Melt-curve analysis was performed to ascertain specific 
amplification. Primers for cDNA were, if possible, designed to span introns to 
avoid amplification of genomic DNA. Analysis of the relative expression levels was 
made using the ΔΔCT method, thereby determining differences in fold change and 
standard deviation in transcript levels. CT values were obtained from the linear 
phase of the logarithmic amplification using the 7500 software. Gene expression 
was normalized to GAPDH, ARHGDIA, or 36B4 mRNA. Biological replicates 
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analyzed in separate qPCR runs were combined according to previously described 
standardization procedures (101). 
 
2.6 Immunoblotting 
Cells were washed twice in cold PBS, then scraped of the plate in cold PBS and 
transferred to a microcentrifuge tube. Subsequently, they were pelleted by 
centrifugation at 1,000 RPM for 10 min at 4°C. Pellets were resuspended in 50-
200 μl RIPA buffer (Thermo Scientific, volume according to size of pellet) with 
1× complete protease inhibitor (Roche Applied Science, Indianapolis, IN). Cell 
suspension was incubated at 4°C for 20 min on an agitating thermomixer before 
centrifugation at full speed for 20 min at 4°C. The supernatant was collected and 
protein concentration measured by the Pierce 660 nm Protein Assay (Thermo 
Scientific), according to manufacturer’s instruction and with a BSA standard. 
 
2.7 Statistical analyses 
Unless otherwise stated, statistical significance of data was assayed using two-
sample Student’s t-test with two-tailed distribution, assuming homoscedasticity, 
error bars show one standard deviation, and asterisks are used as follows: * p < 
0.05, ** p < 0.01, and *** p < 0.001. 
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3.  Chapter 1: Estrogen receptor alpha regulates 
pro-proliferative ion channel KCNK5 
3.1 Introduction 
Our group has previously reported a microarray study aimed at understanding the 
interactions of ERα and ERβ at the level of gene regulation in breast cancer cells 
(102). In this screen, one of the genes most highly induced by estrogen in T47D 
cells was the two-pore domain potassium channel K2P5.1, more commonly known 
as KCNK5 or TASK-2. Interestingly, in T47D cells overexpressing ERβ, we found 
downregulation of KCNK5, suggesting that this gene is regulated in opposite ways 
by both types of ER (102). 
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KCNK5 is a pH-sensitive potassium channel expressed in many different tissues 
including liver, pancreas, small intestine, and kidney (103). KCNK5 currents are 
activated by alkaline intra- or extracellular pH and inhibited by acidic pH on 
either side of the membrane (104,105). KCNK5 channels are insensitive to the 
classical potassium channel blockers tetraethylammonium (TEA) and 4-
aminopyridine but are inhibited by quinidine (103) and the antiarrhythmic agent 
clofilium (106). The expression and function of KCNK5 channels in cells derived 
from mammary epithelium have not been previously studied. Aside from 
important functions of this ion channel in the control of HCO3! excretion by the 
kidney (107), KCNK5 is required for the regulatory volume decreases in response 
to hypotonicity (106,108) and during apoptosis (109). Recently, a role for this 
channel in central chemoreception has been described in mice (110). 
 
We hypothesized that this ion channel may be important in breast cancer, based 
on literature proposing that potassium channels are potential targets for cancer 
therapeutics (111). Different channels, although not KCNK5 specifically, have 
been shown to have effects on proliferation, sensitivity to growth signals, evasion 
of apoptosis, angiogenesis, and metastasis and invasion in some cancers (112), 
and their inhibition is associated with decreased cell proliferation (113,114). The 
mechanisms underlying the role of potassium channels in cell proliferation are 
poorly understood and could result from effects on membrane potential, calcium 
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homeostasis, and/or cell volume regulation, all of which can influence proteins 
directly involved in the cell cycle (112,115–120). Potassium channels can also 
control cell proliferation by regulating the activity of transporters involved in pH 
control (121–124). In the present study we describe the induction of KCNK5 by 
17β-estradiol (E2) in ERα-positive breast cancer cell lines and provide evidence 
that this channel is required for estrogen-induced proliferation. 
 
3.2 Supplemental material and methods 
3.2.1 siRNA transfection 
A pool of four siRNAs (ON-TARGETplus SMARTpool) was used to silence KCNK5. 
As a control, a non-specific siRNA was used. Transient transfections were carried 
out using DharmaFECT 1 Reagent (all siRNA products from Dharmacon, 
Waltham, MA) according to manufacturer’s instructions. All transfections were 
done with cultures in antibiotic-free medium and transfection reagent was washed 
out 24 h after transfection. 
 
3.2.2 ChIP-qPCR 
ChIP was carried out using 2 μg anti-ERα antibody or normal rabbit IgG (Santa 
Cruz Biotechnology), bound to 10 μl Dynabeads Protein G (Life Technologies). 
Binding was carried out by overnight incubation at 4°C with gentle agitation, after 
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washing of beads with BSA/PBS (0.5% weight/volume) thrice. Synchronized cells 
in 15-cm plate were treated with 10 nM E2 for 45min or 10 nM ICI for 24 h. Cells 
were crosslinked with 1.5% formaldehyde in PBS. Crosslinking was stopped with 
125 mM glycine after which cells were scraped in 100 mM Tris-HCl (pH 9.4) and 
10 mM dithiothreitol. Nuclei were isolated by sequential resuspension in NCP 
buffer I (10 mM EDTA; 0.5 mM EGTA; 10 mM HEPES, pH 6.5; 0.25% Triton X-
100), NCP buffer II (10 mM EDTA; 0.5 mM EGTA; 10 mM HEPES, pH 6.5; 200 
mM NaCl), and lysis buffer [10 mM EDTA, 20 mM Tris-HCl (pH 8.0), 0.5% 
Empigen BB, 1% sodium dodecyl sulfate, 1× complete protease inhibitor (Roche 
Applied Science))]. Chromatin was sonicated to an approximate fragment size of 
200-1000 bp and incubated overnight at 4°C with bead-bound antibody in 2 mM 
EDTA (pH 8.0), 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, and 
1× complete protease inhibitor. The beads were washed before elution with 
different buffers, and samples were eluted with 0.1 mM NaHCO3, 1% sodium 
dodecyl sulfate at 65°C. Crosslinking was reversed overnight at 65°C, and DNA 
was purified using MinElute PCR Purification Kit (Qiagen). Input samples were 
diluted 1:50 before. Enrichment of binding was calculated as percentage of input 
(125).  
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3.2.3 Immunoblot 
Primary antibody against KCNK5 (Alomone Laboratories, Jerusalem, Israel) was 
used at 1:200 dilution for incubation overnight.  
 
3.2.4 qPCR primers 
For detection of KCNK5 mRNA the following primer pair was used: F: 5’-
CGGCTTCGGTGACTTTGTG-3’ and R: 5’-AGCTCCACGAAGTAGCGGTACA-3’. 
 
Primers used for ChIP-qPCR were pS2 promoter (F: 5’-
GGCCATCTCTCACTATGAATCACT-3’, R: 5’-GGATTTGCTGATAGACAGAGACGA-
3’), KCNK5 enhancer (F: 5’-AGGTGGAGTGGAAGCTCAAAAC-3’, R: 5’-
CCTCTCCCTGGTCTTTTGCA-3’), pS2 3’-UTR (F: 5’-CCCCAGCACGGTGATTAGTC-
3’, R: 5’-GATCTGCCTGCATCCTGAC-3’), and KCNK5 exon 4 (F: 5’-
GCAGATCACGTGCACAGTCAT-3’, R: 5’-TTCCACCCCTCAGTCACCAT-3’). 
 
3.3 Results 
3.3.1 Estrogen induced an increase in KCNK5 at the mRNA and protein levels 
in T47D and MCF7 cells 
We have in a previous study reported that KCNK5 mRNA is highly regulated by E2 
in T47D cells (102). To confirm this result, we measured KCNK5 mRNA levels in 
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E2-treated T47D and MCF7 cells using qPCR. A time series over 72 h showed that 
the transcription of KCNK5 is rapidly induced by E2 in both cell lines (Figure 
3.1A). Additional experiments indicate that this is likely a direct effect of ERα-
mediated gene regulation. At least three prior genome-scale studies of ERα 
binding in breast cancer cell lines have found the receptor to bind in a potential 
enhancer region upstream of the transcription start site of KCNK5 (126–128). We 
verified that 15 min of E2 treatment causes ERα to bind to this region of the 
genome by chromatin immunoprecipitation (ChIP)-qPCR. We found that ERα 
binding is enriched in the region, as well as on the promoter of the prototypical 
E2-target gene pS2 (TFF1), but not in exonic or 3’-untranslated regions of these 
genes (Figure 3.1B). Moreover, ERα binding to the enhancer of KCNK5 was not 
observed in MCF7 cells pretreated with the ERα-degrading compound ICI 182,780 
(ICI) (Figure 3.1B). In accordance with this, the transcription of KCNK5 in MCF7 
cells treated with either ICI or antagonist tamoxifen, in regular non-starved 
medium, was reduced below the levels of vehicle treatment, further supporting 
the notion that ERα is regulating this gene (Figure 3.1C).  
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Figure 3.1 KCNK5 is induced by estrogen in ERα-positive breast cancer cells. Time course for 
E2 induction of KCNK5 mRNA in A) T47D and B) MCF7, after treatment with 10 nM of E2 after 
synchronization of cells (n = 2). C) ChIP-qPCR showing binding of ERα at the promoter of its 
archetypical target gene pS2, as well as in an enhancer element of the KCNK5 gene. IgG used as 
negative control for the immunoprecipitation, antagonist ICI for the treatment, and two negative-
control sites for the specificity of the binding. (n = 3). D) qPCR showing mRNA levels of KCNK5 
after 24 h of indicated treatments. Cells were grown in complete medium and without 
synchronization prior to treatment. Ethanol and DMSO are vehicle controls and ICI and tamoxifen 
(Tam) antagonists for ERα. Error bars represent SEM in this and following figures in this chapter. 
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To test whether E2 also increased KCNK5 protein, we carried out immunoblot 
analyses of extracts obtained from synchronized MCF7 and T47D cells at different 
time points after the start of E2 treatment. An increase in KCNK5 protein was 
observed in both cell lines at 12 h after the start of treatment and lasting for 48–
72 h (Figure 3.2). 
 
 
Figure 3.2. Estrogen-induced increase in KCNK5 mRNA reflected on protein levels. Time 
course for induction of KCNK5 at protein level, after treatment with 10 nM of E2 over indicated 
time, for A) T47D and B) MCF7. Cells were synchronized prior to treatment. Bar graphs show 
quantification of replicated immunoblots (n ≥ 3). 
 
3.3.2 Silencing of KCNK5 reduced E2-induced proliferation of T47D cells 
To further examine the effect on the ERα-mediated regulation of KCNK5 we chose 
to silence its expression using siRNA. Transient transfection with siRNA targeting 
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KCNK5 effectively reduced the mRNA levels up till at least 72 h (Figure 3.3A). 
However, this change was not consistently reflected by a decrease in protein 
levels (Figure 3.3.B). This is likely explained by the fact that the KCNK5 protein’s 
half-life is long. Three repeated transfections over 6 days did produce a significant 
decrease in protein levels (129).  
 
 
Figure 3.3. Reduction in KCNK5 expression following siRNA treatment. Treatment of T47D 
cells with control siRNA (scrambled sequence) or siRNA targeting KCNK5. A) Bar graph 
illustrating effects on KCNK5 mRNA following one and three days of siRNA treatment. B) 
Immunoblots showing effect on KCNK5 protein levels after 24 and 48 h of siRNA treatment. 
 
We next assessed the effect of the reduced ion channel levels on the cell cycle of 
the cells. Both cell counts and MTS assay results indicated lower proliferation in 
cells treated with siRNA for KCNK5, and the E2-induced cellular proliferation was 
partially blocked (129). We then carried out flow-cytometric analysis to further 
dissect this change. E2 stimulated cells treated with KCNK5 siRNA were more 
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likely to remain in the G1 phase of the cell cycle, compared to cells treated with 
control siRNA (Figure 3.4). This indicates that reduction in KCNK5 levels induces 
G1/S cell cycle arrest. 
 
 
Figure 3.4. Cell-cycle analysis of siRNA-treated cells. Cells were treated with control or KCNK5-
targeting siRNA over 24 h, followed by flow-cytometric analysis of DNA content. Numbers in 
graphs show percentage of cells in the G1 phase of the cell cycle at indicate time point and 
treatment. Significance indicated according to Material and methods section. 
 
3.4 Conclusion 
Other results from this study, obtained from C. Alvarez-Baron, also showed that 
E2 treatment of T47D and MCF7 cells increases currents indicative of KCNK5 
activity at the plasma membrane. This increase was also partially blocked in T47D 
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cells by clofilium, an inhibitor of KCNK5. Additionally, immunofluorescent 
labeling of the ion channel demonstrated that it was localized at the membrane, 
as expected, but also largely in intracellular compartments. 
 
KCNK5 channels may contribute to the pathogenesis of cancer. For example, a 
recent study of a large number of primary human cancers and cancer cell lines 
identified an amplification in a region located on 6p21.2 that contained eight 
genes including KCNK5, as well as the closely related genes KCNK16 and KCNK17 
(130). Moreover, they found upregulation of KCNK5 transcripts in several of the 
cancer cell lines that they examined. Other channels in the two-pore domain 
potassium channels family have also been implicated in cancer. For example, the 
KCNK9 gene, which encodes a potassium channel that is also inhibited by 
extracellular acidification, is significantly amplified in 10% of breast tumors, and 
its transcript is markedly overexpressed in 44% of breast tumors (131). Cells over-
expressing KCNK9 are resistant to hypoxia. Given the similarities in function, it is 
possible that multiple members of this family of channels may play a role in 
allowing cells to adapt to the relatively anoxic microenvironment of solid tumors. 
In this regard, KCNK5 and KCNK9 have been reported to play a similar role in 
protecting cells from stress (132), and the potential mechanisms whereby these 
channels may regulate proliferation and apoptosis need to be further studied, but 
may be unrelated to channel activity per se (133). 
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Our results, therefore, offer an enhanced view of the mechanisms whereby ERα 
induces proliferation. In addition to the known direct upregulation of the pro-
proliferative proto-oncogene MYC, we show that ERα induces the KCNK5 ion 
channel and that this is necessary for normal estrogen-induced proliferation. The 
effect of KCNK5 on proliferation suggests that this channel could be a useful 
pharmacological target for treatment of ERα-positive breast cancer. ERα-positive 
tumors account for the majority of breast tumor diagnoses. At present, the only 
targeted therapy is treatment with antiestrogens or aromatase inhibitors. The side 
effects of these treatments and the development of resistance over time suggest 
the importance of finding new strategies to target ERα-positive tumors. Targeting 
KCNK5 would block the proliferation-inducing ability of ERα, specifically, while 
preserving more beneficial activities, such as the differentiation- and apoptosis-
inducing effects of ERα. Such a targeted therapy would be an alternative also for 
refractory ERα-positive cancers. Unfortunately, adequately specific blockers for 
KCNK5 are not currently available, and the available inhibitors exhibit high 
toxicity in vivo at the doses required to block KCNK5 (134). 
 
In summary, we have shown that KCNK5, a pH-sensitive potassium channel in the 
two-pore superfamily, is induced by estrogen in ERα-positive breast cancer cell 
lines, and that this channel is required for normal E2-evoked proliferation in these 
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cells. KCNK5 and related channels may therefore represent potential targets for 
breast cancer therapeutics. 
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4.  Chapter 2: Single-molecule sequencing of the 
estrogen-induced transcriptome in breast cancer 
cells 
4.1 Introduction 
The effort to characterize ERα’s role in the cellular biology of BC is mainly 
concerned with understanding the gene-regulatory role it plays, being that it is a 
ligand-regulated transcription factor. The arrival of next-generation sequencing 
(NGS) facilitates this endeavor, by allowing for assessment of DNA binding and 
expression of any genomic element on a global scale and in an un-biased manner. 
A wide number of studies have dissected the genomic binding of ERα 
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(126,135,136), revealing that the receptor can bind to anywhere from 1,000 to 
15,000 different loci. Not as many studies have been done to study the ensuing 
effect on gene regulation with said NGS technology, but it has been shown that 
ERα can regulate 3,386 protein-coding genes (137). Another study, assessing 
nascent transcripts upon stimulation with E2, found approximately 6,000 
transcripts (coding and non-coding) to be regulated (138). 
 
Although the existence of non-coding RNAs (ncRNAs) has been known for 
decades, it was not until recently that their importance in development and 
disease was revealed. Initially believed to be transcriptional “noise”, the extensive 
transcription across the whole genome is now, by most, considered to be of 
biological relevance. Aside from components of the splicing and translational 
machinery, the class of ncRNAs comprises small non-coding RNAs (e.g. miRNAs) 
and long non-coding RNAs (lncRNAs), the latter being defined as RNAs larger 
than 200 bp. Like mRNAs, lncRNAs have exons and introns, are largely 
polyadenylated, and exist in splice variants, yet in most instances lack even the 
potential to code for protein (139,140). They are expressed at lower levels than 
mRNAs (141). Although still scarce, the evidence of well-characterized functional 
roles for lncRNAs is increasing. Their demonstrated functions are diverse, ranging 
from chromatin modification, regulation of transcription and translation, to 
modulation of protein function through direct interactions (142). Importantly, it 
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has been shown that lncRNAs exhibit higher tissue-specific expression than 
protein-coding genes, and are expressed at specific stages of development 
(139,142–144). 
 
The fact that the majority of cancer-risk associated loci lie outside of protein-
coding regions of the genome, together with the findings of cancer-regulatory 
roles of individual lncRNAs, highlight the potential of this class of molecules to 
impinge on tumor progression (145,146). The lncRNA HOTAIR, aside from 
implied roles in other cancers, is associated with metastasis in ERα-positive breast 
cancer and has been reported to be induced by E2 (147,148). One demonstrated 
function of HOTAIR is the binding to polycomb repressive complex 2, by which 
breast cancer cells turn on a metastatis-promoting set of genes (149). 
 
In this study, we aimed to utilize novel sequencing technologies in order to 
uncover new aspects of the E2-ERα transcriptome. We chose to single-molecule 
sequence the polyadenlyated RNA fraction for precision, lack of amplification-
induced biased, and to cover both protein-coding and non-coding RNAs 
(150,151). Also, in a further attempt to understand the transcriptional program 
controlled by ERα in breast cancer cells, we studied its interaction with the pro-
proliferative transcription factor activator protein-1 (AP-1). Also, we studied how 
endocrine-disrupting chemicals (EDCs) can activate ERα, in comparison to 
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estradiol and in combinatory treatments. This in order to further understand the 
possible health effect of human exposure to such compounds (152). 
 
4.2 Supplementary material and methods 
4.2.1 Library preparation and sequencing 
Total RNA was extracted as described above, and thereafter twice enriched for the 
polyA+ fraction by separation with oligo(dT) magnetic beads. Enrichment was 
ensured by use of the mRNA Nano kit for Agilent Bioanalyzer 2100. Sample 
libraries were prepared and subjected to direct RNA sequencing by Helicos 
Biosciences, whose technology has been described (150,153–155). In short, this 
included heat fragmentation, cDNA synthesis, and the addition of a poly(dA) tail 
to cDNA, before poly(dT) capture on the sequencing flow-cell, and sequencing by 
synthesis through addition of fluorescently labeled nucleotides. Biological as well 
as technological duplicates were analyzed. 
 
4.2.2 Data analysis and bioinformatics 
Raw reads were filtered according to length and base composition, as previously 
described (154). Remaining reads were aligned to the human transcriptome 
(assembly hg19 with Gencode 19 as annotation) using the GSNAP (156) and 
STAR (157). GSNAP was run with parameters allowing for 3 mismatches and 
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detection of novel splice sites, with all other alignment parameters at default 
value. STAR was run with parameters allowing for 3 mismatches, no multi-
mapped reads, with all other parameters at default value. 
 
Remaining bioinformatics analyses were carried out in R, using packages edgeR 
(158) and DESeq2 (159) for normalization of count data, and to test for 
differential expression. A cut-off value for expressed transcripts was set at 1 read 
per million reads (RPM) per sequenced sample. For differential expression, the 
union of transcripts from analysis with both programs, with absolute fold change 
> 1.5 at FDR 5%, were used. 
 
4.3 Results 
4.3.1 Single-molecule sequencing of the E2-ERα-transcriptome 
Samples were verified to show typical E2 induction of the classical ERα target 
gene pS2. The polyadenylated fraction of RNA was subjected to sequencing, in 
technical and biological duplicates. The resulting sequencing reads were filtered 
for technical artifacts, the resulting number of reads per sample is listed in Table 
4.1. Subsequently, the reads were aligned to the annotated human transcriptome, 
with alignment software allowing for splice alignment, i.e. reads spanning spliced 
sites. The resulting number of aligned reads is shown in Table 4.1. Aside from 
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reads containing sequencing errors, the remaining number of sequences could 
possibly be un-annotated RNA (155). To assess the biological variation, we 
analyzed the correlation between replicated treatments (Figure 4.1). For all but 
one treatment, the correlation coefficient was larger than 0.90. Apparent technical 
variation in one replicate for the vehicle-treated T47D led us to omit this from the 
remaining analyses.  
 
Table 4.1. Summary of RNA-sequencing and sequence alignment. Shown are total number of 
sequencing reads after quality filtering, and reads aligned with either of the indicated aligners.  
 
 
 
 
 
For the remainder of the analyses, we sat a cut-off for expression at 1 sequence 
read per total million reads (RPM) (150). At that cut-off, we found 18,402 and 
17138 transcripts to be expressed in MCF7 and T47D, respectively, in either of 
two replicates per treatment. The majority of the transcripts were protein-coding 
genes, followed by non-coding RNAs and pseudogenes (Figure 4.2A). A fraction of 
small non-coding RNAs (including e.g. miRNAs) were detected too. Ribosomal 
and mitochondrial reads were discarded.  
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Figure 4.1. Correlation between biological replicates.  Biological and technical duplicates were 
sequenced. Scatter plots show tag count per million reads (RPM) for features in genomic 
annotation. Data plotted on log scale, omitting transcripts with RPM < 1. 
 
4.3.2 E2-ERα induced changes in the coding and non-coding transcriptome 
Next, we conducted analysis of differential expression (DE) between E2- and  
vehicle-treated cells. For MCF7 and T47D, we observed 2,462 and 3,369 DE 
transcripts, respectively (Figure 4.2B-C). The higher number in T47D likely 
reflects the omitted vehicle replicate, i.e. a higher likelihood of false positives. The  
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Figure 4.2. Full MCF7 and T47D transcriptome and E2-mediated changes.  A) Distribution of 
transcript types among genes expressed in at least one of two replicates per treatment, in both 
cells lines. Ribosomal and mitochondrial RNA omitted. B) Similar to A), but for transcripts 
determined to be differentially expressed. C) Venn diagrams showing overlaps between cell lines 
of all differentially expressed transcripts, as well as only protein-coding and non-coding RNAs, 
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respectively. D) Fraction plots illustrating percentage of up- and downregulated transcripts, 
respectively, among the sets of common or cell-line specific transcripts. 
 
distribution of transcript types largely reflected that of the total expressed 
transcriptome, i.e. consisting predominantly in protein-coding RNAs but also 
other RNA species. However, relative to all expressed transcripts there was 
possibly an overrepresentation of DE lncRNAs in T47D. We found overlaps of 472 
protein-coding and 178 and non-coding DE RNAs, respectively, between the 
MCF7 and T47D comparisons (Figure 4.2C). We found the majority of regulated 
genes to be induced, rather than suppressed, by E2 (Figure 4.2D) (138). This is 
likely a result of the chosen time point (8 h) and the assay technology as 
repressed genes are commonly found in larger numbers at later time points (Hah 
et al. measure nascent transcripts, as opposed to processed ones). 
 
The biological function of the DE transcripts was assessed by enrichment analysis 
of gene ontology (GO) biological processes among the common protein-coding 
genes, as well as among the whole sets of DE transcripts for MCF7 and T47D 
(Table 4.2). As expected, there was a significant overrepresentation of terms 
associated with cellular division and proliferation, indicative of the mitogenic role 
of E2 and ERα. Also, apoptosis-related GO terms were enriched for, concordant 
with the fact that ERα is capable of stimulating both proliferation and cell death 
(160,161). 
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Table 4.2. Enrichment of gene ontologies among differentially expressed transcripts. Select 
GO terms for biological processes overrepresented in DE analysis, from common, MCF7, and T47D 
datasets. Note that most non-coding RNA species are not annotate to GO terms. Overlapping terms 
were omitted. N shows number of genes in category represented in DE analysis. 
 GO term Description N P value 
Co
mm
on
 GO:0006412 Translation 50 9.1E-14 
GO:0022411 Cellular component disassembly 47 1.6E-13 
GO:0010467 Gene expression 209 1.9E-10 
GO:0019438 Aromatic compound biosynthetic process 177 2.2E-09 
GO:0019222 Regulation of metabolic process 192 4.6E-03 
M
CF
7 
GO:0007049 Cell cycle 271 1.8E-40 
GO:0034660 ncRNA metabolic process 97 1.1E-35 
GO:0050896 Response to stimulus 6819 4.2E-35 
GO:0006915 Apoptotic process 220 1.2E-18 
GO:0008283 Cell proliferation 225 3.4E-18 
T4
7D
 GO:0022904 Respiratory electron transport chain 28 3.7E-07 GO:0045216 Cell-cell junction organization 46 5.7E-05 
GO:0050896 Response to stimulus 837 8.2E-04 
GO:0008219 Cell death 243 1.2E-03 
GO:0007049 Cell cycle 207 7.7E-03 
 
4.3.3. RNA-seq of E2-ERα transcriptome uncovered potential novel targets 
In order to explore the set of changed transcripts further, we integrated prior data 
into our dataset. We analyzed The Cancer Genome Atlas’s (TCGA) available data 
of gene expression in breast tumors (7) for correlation of our DE transcripts to the 
expression of ERα (ESR1) (Figure 4.3A). We carried out this analysis for all 
tumors, as well as for the luminal A-only cohort, revealing 161 genes, out of the 
common set of 472 genes, to be correlated significantly correlated with ERα 
mRNA in all tumors, in a direction concordant with their regulation in the cell 
lines. Of the aforementioned 161 genes, 108 were not identified in two previous 
studies aimed to define ERα targets (136,138). This number was slightly lower, 
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142, when only the luminal A tumors were included. For the MCF7 and T47D 
gene sets, the equivalent numbers were 576 and 704, respectively, for all tumors, 
and 765 and 546, respectively, for the luminal A tumors. Together, these numbers 
indicate that many of our identified DE transcripts are de facto targets of ERα in 
human breast tumors. The higher number of significantly correlated genes for 
MCF7 among the luminal A tumors likely reflects the more “luminal nature” of 
this cell line, and possibly the effect of the omitted replicate. Thereafter we 
annotated our set of DE genes with known genomic binding sites for ERα, as 
assessed by ChIP-seq in both cell lines from previous publications (162,163). Of 
the differentially expressed protein-coding genes, a majority had ERα-binding 
sites within 50 kb of their transcription start sites, according to at least one of the 
two datasets used, and this was also reflected by the high proportion of protein-
coding genes regulated in either cell line with binding sites (Figure 4.3B). The 
same was true for lncRNAs. However, as ERα often binds distal to promoters and 
interacts with target genes through chromatin looping, it is not always clear 
which, if any, genes whose promoters ERα binds that it also regulates (164).  
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Figure 4.3. Integrative analyses of our sets of differential expression and prior data. A) Plots 
showing protein-coding transcripts whose expression correlates significantly with ERα mRNA 
(ESR1; negative correlation in green, positive in red, and non-significant correlations in black) in 
the TCGA dataset of human breast tumor gene expression (7). Left plot shows data for all tumors 
and right plot shows data for only the luminal A tumors. B) Histograms showing the number of DE 
transcripts from our study that also have ERα-binding sites according to published ChIP-seq 
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studies (162,163). For common genes, binding sites found in either cell line was included, and for 
the cell-line specific gene sets only binding sites from corresponding cell line was included. 
 
We confirmed the RNA-seq data for select protein-coding genes (Figure 4.4A). 
The regulation of some targets, e.g. PKIB and GPR132, were exclusive for either 
cell line. Two long intergenic RNAs (lincRNAs) were confirmed to be upregulated 
by E2 in both MCF7 and T47D. Both also have ERα-binding sites, intergenic and 
in their promoter regions We confirmed the upregulation of both lincRNAs and 
noted that they are both induced significantly within an hour of E2 treatment 
strongly suggesting them being direct targets of ERα (Figure 4.4B). We also found 
ERα-binding sites close to both lncRNAs (162,163), and these binding sites 
overlapped with DNase-hypersensitivity regions, which suggest open chromatin at 
the sites. Indeed, ChIP-qPCR confirmed ERα binding at three out of four assessed 
sites, further supporting the notion of these lncRNAs as direct targets of ERα. 
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Figure 4.4. Confirmation of RNA-seq data by qPCR. A) Protein-coding genes induced by E2 
according to RNA-seq in either both cell lines (PGR, MYB), MCF7 only (PKIB), or T47D only 
(GPR132). First two bars for each gene represent data from qPCR analysis, average for two 
replicates. B) Time series over 72 h of E2 induction of select lncRNAs. C) Left, gene models of 
indicated lncRNAs showing ER)-binding sites from the literature and their positions relative to the 
TSS (162,163). Right, ChIP-qPCR for indicated genomic sites for the two lncRNAs, average of two 
replicates.  
 
 48 
4.3.4. Identification of the ERα/AP-1 transcriptome and regulation of 
endocrine-disrupting chemicals 
In another effort to dissect the ERα transcriptome in breast cancer cells, we 
studied the receptor’s interaction with the AP-1 transcription factor. By silencing 
one of the heterodimeric partners of AP-1, c-Fos, we showed that 37% of ERα-
regulated genes were attenuated, pointing at AP-1’s role in cooperatively with 
ERα induce or repress their expression. Moreover, we showed that AP-1 
independently influences the regulation of 5% of the protein-coding 
transcriptome. Analysis for enrichment of gene ontology biological processes 
revealed that E2/ERα/AP-1-induced genes were involved in cellular proliferation 
and that for repressed genes biological processes associated with apoptosis and 
negative regulation of cell proliferation were overrepresented. Genes regulated by 
AP-1 independently of E2/ERα were also involved in cell proliferation. 
Additionally, E2F1 was identified as a direct target of ERα and AP-1 (165) and we 
demonstrated a network of E2F1 target genes were affected by silencing of c-Fos, 
both in a E2/ERα-dependent and –independent manner.  
 
In another part of this study, we aimed to understand to what extent the 
transcriptional response to EDCs differ from that of E2. We studied the changes in 
the protein-coding transcriptome to bisphenol A (BPA), genistein, and 
phytoestrogen-containing soy formula by microarrays (166). This study found that 
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these compounds essentially regulate the same set of genes as E2, through ERα, 
and do not elicit extensive, if at all, non-genomic effects at lower concentrations. 
Moreover, it was shown that the EDCs were additive in their transcriptional 
effects on target genes, and that they were able to induce cellular proliferation 
comparable to the effect of E2. 
 
4.4 Conclusion 
We herein describe out effort to characterize the E2-ERα transcriptome in two 
human breast cancer cell lines by means of single-molecule RNA-sequencing. The 
development in sequencing technologies allows for a wide host of assays to be 
performed at genome-wide scale. In our study we treated MCF7 and T47D cancer 
cell lines for 8 h with E2, an assessed the ensuing effects on the polyadenylated 
transcriptome.  
 
Our findings include a large set of E2-regulated protein-coding genes, in either 
cell line, as well as a set of common genes. This group of genes includes both 
know ERα-target genes, but also targets that have previously not been defined as 
direct targets. Moreover, the analysis revealed multiple lncRNAs as potential 
direct targets of ERα, and we confirmed the regulation of two of these, as well as 
ERα binding in their promoter/gene. Further ERα DNA-binding studies need to be 
carried out to confirm that the receptor in fact binds at these sites upon E2 
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stimuli. Interrogation of the whole set of lncRNAs can possibly find more targets 
of interest and interestingly, we have indications that E2-induced lncRNAs can 
exhibit high association with patient outcome (Cristian Coarfa, Baylor College of 
Medicine). Ultimately, this can aid in the characterization of ERα-regulation of 
non-coding RNAs, beyond protein-coding genes and small non-coding RNAs, such 
as miRNA. Due to the potent regulatory ability of lncRNAs, these are of interest to 
further understand ERα’s role in regular biology as well as in disease. 
 
Furthermore, the data on AP-1’s role in regulating breast cancer cell proliferation, 
dependently and independently of ERα, suggest a critical role for this 
transcription factor in the proliferation of these cells, concordant with previous 
data (39,167,168). Also, we showed that part of this proliferative response might 
be mediated by direct regulation of E2F1, which in its turn regulates a 
proliferative program. This is in line with proposed E2F1-targeting small 
molecules for breast cancer treatment (169). 
 
Finally, the examination of the ability of EDCs to regulated E2/ERα target genes 
showed that these compounds do not regulate subsets of genes distinct from E2, 
but that they can have additive effect when cells are exposed to more than one. 
They are also capable of inducing cellular proliferation similarly to E2, warranting 
further research into human exposure to EDCs out of a health perspective. 
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5.  Chapter 3: Support of a bi-faceted role of ERβ in 
ERα-positive breast cancer cells 
5.1 Introduction 
The role of estrogen receptor alpha (ERα, ESR1) as a biological marker and target 
in breast cancer therapy is clear. ERα antagonists, such as tamoxifen, or estrogen 
ablation using aromatase inhibitors are efficient therapeutic approaches in the 
treatment of ERα-positive breast cancer. A second estrogen receptor, ERβ (ESR2), 
was discovered in 1996 (35,170) and is considered the predominant ER in normal 
breast (35). Clinical studies indicate that whereas ERβ expression is low in breast 
and decreases further during tumor progression (51,59,75–77), a large 
proportion, between 39% and 77%, of all breast cancer tumors co-express both 
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ERs (Figure 1.3) (61–73). ERβ is therefore a potential marker and target, in these 
tumors, that could enhance the use of endocrine therapy. Albeit both ERs are 
activated by estrogen, their ligand-binding domains allow for receptor-selective 
ligands. Their DNA-binding domains are highly conserved and they share between 
46% and 73% of chromatin-binding sites (Figure 1.1) (42), although distinct 
regions of binding have also been defined for each receptor (38–40). The 
receptors’ N-terminal domains are structurally different and lead to different 
abilities in their interaction with coregulators (171), resulting in a higher 
transactivation capacity for ERα (170). 
 
The function of ERβ in breast cancer is not clearly understood (79) and ERβ is 
currently not used in the diagnosis or treatment of breast cancer patients. One 
obstacle in the field is that available breast cancer cell lines do not express 
sufficient levels of endogenous ERβ for consistent mechanistic and functional 
studies (172) and mRNA levels in tissues are also persistently low in comparison 
to ERα (173). To explore its role, ERβ thus has to be introduced exogenously. The 
majority of studies has used transient or inducible induction of ERβ and indicates 
that ERβ in ERα-positive breast cancer cells counteracts the proliferative and 
transcriptional functions of ERα (102,174–178). Whereas some clinical studies 
link ERβ expression to better outcomes (84,179,180), others have correlated ERβ 
expression to the proliferation marker Ki67 in primary breast tumors (63,78,181) 
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and associated its expression with a higher risk of relapse in node-positive breast 
cancer patients (66). In ERα-negative tumors, ERβ expression has been correlated 
to a higher aneuploidy, indicative of a more aggressive phenotype (61). The body 
of data correlating ERβ to both anti-proliferative and proliferative parameters has 
led to the suggestions of a bi-faceted role for ERβ (79). One clinical study 
indicated that tamoxifen treatment of ERβ-positive tumors may be beneficial: ERβ 
was associated with better survival after long-term tamoxifen-treatment in post- 
but not pre-menopausal women (65). A deeper understanding of the role and 
mechanism of ERβ may help us improve the treatment for breast cancer patients.  
 
We set out to investigate the effect of constitutive expression of ERβ in breast-
cancer cells. Our aim in this study was to complement the studies of transient or 
short-term effects of ERβ and gain additional insight into its mechanism and 
potential clinical applications.  
 
5.2 Supplementary material and methods 
5.2.1 Cell culture, ERβ expression and treatments 
Duplicate T47D-ERβ and T47D-control, and triplicate MCF7-ERβ and MCF7-
control mixed-cell populations were generated by lentiviral transductions (Dr. A. 
Ström, University of Houston) with CMV-driven, FLAG-tagged full-length ERβ 
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cDNA (530 aa) or empty vector, respectively, and selected as previously described 
(182). Two or three separate transduction replicates in the shape of mixed-cell 
populations, for each control and ERβ cell line, were used for all experiments. 
T47D and MCF7 cells were passaged and serum starved prior to ligand treatments 
as previously described (183,184). E2 (17β-estradiol, Sigma, Saint Louis, MO, 
USA) at 10 nM concentration was used as agonists for both receptors, PPT and 
DPN (Tocris Bioscience, Bristol, UK) at 1-10 nM as selective ligand for ERα and 
ERβ, respectively, KB101471 (gift from KaroBio, Sweden) at 0.5 nM and LY3201 
(gift from Eli Lilly, Indianapolis, IN, USA) at 1 nM were used as selective ligands 
for ERβ. As antagonists, tamoxifen (Sigma) at 1 μM and ICI (Tocris Bioscience) at 
10 nM were used.  
 
5.2.2 ERβ immunoprecipitation 
For immunoprecipitation experiments, cells were harvested from 15-cm plates. 
Cells were incubated in RIPA buffer 5 min, washed twice with cold PBS, collected 
in microcentrifuge tubes, passed through a syringe, and incubated at least 4 h on 
a nutator at 4°C. Supernatants were collected as described above, and protein 
concentration determined. Equal amounts of protein were used for each IP, which 
was performed with Anti-FLAG M2 affinity gel (Sigma), as described by 
manufacturer. Essentially, part of the input was saved before incubating lysates 
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overnight on a nutator at 4°C. Samples were boiled in Laemmli sample buffer 
(Bio-Rad, Hercules, CA) 5 min before performing immunoblotting. 
 
5.2.3 Ligand-binding assay 
Ligand-binding assays were carried out with tritium-labeled E2. Cells were plated 
in 6- or 12-well plates and grown to an approximate confluency of 50%, 
thereafter washed thrice with PBS before incubation for 3 h with 0.5 nM [3H]-
17β-estradiol (American Radiolabeled Chemicals, St. Louis, MO), with the 
addition of 1 μM unlabeled E2 in half of the wells. Treatment was carried out in 
medium supplemented with 5% DCC-FBS and PenStrep. Subsequently, the cells 
were carefully washed thrice with cold PBS, lysed with lysis buffer (5 M NaCl, 0.1 
M Tris-phosphate, 1 M DTT, 500 mM EDTA, 50% glycerol, 10% Triton X-100), 
and lysates were added to liquid scintillation cocktail (MP Biomedicals, Santa 
Ana, CA). Radioactivity was measured using a liquid scintillation counter 
(LS6000, Beckman-Coulter, Pasadena, CA) and normalized to total protein 
content. All measurements were carried out in at least triplicates. 
 
5.2.4 Luciferase assay 
Luciferase estrogen-response element (ERE) transactivation assays were carried 
out with cells in 12-well plates at an approximate confluency of 80%. Each well 
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was transfected with 500 ng ERE-TATA-Luc plasmid and 50 ng RSV-gal plasmid 
using Lipofectamin LTX and Opti-MEM (Life Technologies). Cells were treated 
with vehicle and E2 as previously described, before washing with PBS and lysing. 
Lysis buffer and luciferase reagents were from BioVision (Luciferase Reporter 
Assay Kit, Milpitas, CA, USA). Luciferase and X-gal activity was read on a Victor 
X4 Multilabel Plate Reader (PerkinElmer). Luciferase activity was normalized to 
X-gal activity.  
 
5.2.5 Microarray analysis and methodology 
Operon’s long-nucleotide spotted arrays, covering the whole human transcriptome 
(35 000 genes and variants), were used (Microarray Inc., Huntsville, AL). Each 
comparison (ERβ vs. mock) was performed in duplicate and dye-swapped to 
account for variance in sampling and labeling efficiency. 
 
For each sample cDNA synthesis was carried out using 20 μg total RNA as starting 
material. This was mixed with 5 μg random hexamer primer (Operon, Ebersberg, 
Germany), incubated at 70°C for 10 min, on ice for 5 min before adding reverse-
transcription mixture to a total volume of 30 μl. The mixture contained 400 units 
Superscript III, 1× first-strand buffer, 0.01 M DTT (all Life Technologies) and 0.5 
mM dNTP mixture with a ratio of aminoallyl-modified dUTP to dTTP of 4:1 
(Sigma). Subsequent to 10 min of incubation at 25°C the enzymatic reaction was 
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run 2 h at 46°C. The RNA strand was hydrolyzed in 16 mM EDTA pH 8.0 using 
120 mM NaOH for 15 min at 70°C. The reaction was cooled to room temperature 
and neutralized with 120 mM HCl whereafter cDNA was purified using MinElute 
PCR Purification Kit (Qiagen), where provided wash and elution buffers were 
replaced by 80% ethanol and 100 mM NaHCO3 pH 9.0. Elution was repeated, 
yielding 20 μl in total. To the eluate one tenth of either of the Cy3 or Cy5 
monoreactive NHS-ester dye tubes, dissolved in DMSO, and dried in vacuum 
centrifuge, was added. Labeling mixture was incubated for at least 30 min in dark 
at room temperature prior to purification with MinElute PCR Purification Kit, 
using provided solutions.  
 
Cy3 and Cy5 samples were pooled and vacuum-centrifuged to 13.6 μl or below. 
Thereafter a hybridization mixture of 5× SSC, 50% formamide (both Sigma), 
0.1% SDS pH 6.6 (Life Technologies), 0.1 μg/μl tRNA (Sigma) and 0.2 μg/μl Cot-
1 DNA (Life Technologies) was added to a total volume of 65 μl. Samples were 
then denatured for 3 min at 95°C and incubated 2 min on ice. Microarray slides 
were pre-hybridized for 30 min at 42°C using a 0.45 μm-filtered solution 
containing 10 g/l BSA (Sigma), 5× SSC and 0.1% SDS pH 6.6, this to minimize 
unspecific hybridization. Thereafter the slides were washed with water and 
isopropanol (Sigma) prior to drying in a slide centrifuge. Slides were put in 
hybridization chambers (Corning, Corning, NY), samples applied under LifterSlip 
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covers (Erie Scientific Company, Portsmouth, NH) and then hybridized for at least 
40 h in water bath at 42°C. Post-hybridization washing of slides was carried out 
sequentially using three buffers with decreasing SDS/SSC concentration. First 
slides were washed for 5 min at 42°C agitated at 60 RPM with buffer containing 
2× SSC and 0.1% SDS. Next wash step was for 5 min at room temperature at 60 
RPM using buffer containing 0.1× SSC and 0.1% SDS. Finally slides were washed 
1 min at 60 RPM using buffer containing 0.1× SSC. The ultimate washing step 
was repeated four times. 
 
Slides were scanned using an Axon GenePix 4400A (Molecular Devices, 
Sunnyvale, CA) to obtain TIFF-images for data processing. Scanning was carried 
out at 10-μm resolution, focus position 10 μm and the PMT gain adjusted to 
obtain a balanced image in terms of both scanned channels (635 and 532 nm 
respectively), separately for each scan. TIFF-images were analyzed in GenePix Pro 
6.1 (Molecular Devices). The images were manually inspected for irregularities 
and then software analysis was performed calculating foreground and background 
intensities for the spots. For further identification of differentially expressed (DE) 
genes, the data was analyzed in the R environment using the packages: limma 
(185), aroma (186) and custom scripts. A spot on the array was removed from the 
data if GenePix had flagged it as “Bad” or “Not found”, or if it did not fulfill 
following requirements: a) its foreground intensity was to low compared to the 
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background, b) its mean and median intensity values, for both channels, deviated 
too much, c) the ratio of median intensity for the two channels differed too much 
from the median of the ratio of the two channels, d) it was not within the size 70 
to 171 μm, or if e) it was saturated in one or both channels. This was done using 
functions in the KTH-package. Remaining intensity data was normalized using the 
print-tip group lowess method within the aroma package (187). Thereafter a 
linear model using least-square method was fit for each gene and the empirical 
Bayes moderated t-test applied to the data, both using the limma package. This 
generated a list of DE genes with B scores – the probability for DE as calculated by 
Bayes statistics. Genes of interest, subjects for confirmation using real-time PCR, 
were chosen among the genes with B values over 0 and an M value (= 
log2[Cy5/Cy3]) higher than 0.4 or smaller than -0.4. Genes that were not 
detected on at least three out of four arrays were discarded. 
 
Overrepresentation/enrichment analyses were carried out in Pathway Studio 
(Elsevier, Philadelphia, PA), using the software’s Gene Ontology gene sets and the 
ResNet motif-based database, and the transcription factor target gene set provided 
by Broad Institute’s Molecular Signatures Database based on TRANSFAC motifs 
(188). P-values indicated in these data are calculated with Fisher’s exact test. 
Microarray data is available on NCBI’s GEO data repository under accession 
numbers GSE45047 and GSE45557. 
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5.2.6 Cell counting and MTS assay 
Cells were seeded at indicated density in 25-cm2 flasks and grown over the 
indicated number of days before counting of viable cells using trypan-blue 
staining. For the MTS assay, cells were seeded in a 96-well plate at density 2,500-
5,000 cells per well and thereafter treated as described above with indicated 
ligands. 
 
5.2.7 Wound-healing assay 
Cell migration was measured using wound-healing (in vitro scratch) assays. The 
assay was carried out with cells seeded in a 12-well plate. Upon confluency, a 
scratch was made with a pipette tip and pictures of the scratch were taken with 
microscope camera at 0 and 24 h. Cells were treated with vehicle or E2 in 0.5% 
DCC-FBS-supplied medium. ImageJ (189) was used to analyze the scratch area, 
which was used to calculate migration. 
 
5.2.8 PARP cleavage 
The cleavage of PARP was examined using anti-PARP antibody (#9542, Cell 
Signaling, Danvers, MA), dilution 1:1,000, detecting full PARP (116 kDa) and 
cleaved fragment at 89 kDa. Relative cleavage was calculated, normalized to β-
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actin. Western blotting was performed as previously described. Ligand treatment 
was done according to standard procedure with the addition of cisplatin at 10 
μg/ml at 0 h. 
 
5.2.9 qPCR primers 
The following primers were used for the qPCR analysis of mRNA expression:  
ERα:   F: 5’-GCTACGAAGTGGGAATGATGAAAG-3’,  
R: 5’-GCTACGAAGTGGGAATGATGAAAG-3’ 
ERβ:  F: 5’-ACTTGCTGAACGCCGTGACC -3’ 
R: 5’-CAGATGTTCCATGCCCTTGTT-3’ 
pS2:  5’-CATCGACGTCCCTCCAGAAGAG-3’ 
R: 5’-CTCTGGGACTAATCACCGTGCTG-3’ 
KCNK5: F: 5’-CGGCTTCGGTGACTTTGTG -3’ 
  R: 5’-AGCTCCACGAAGTAGCGGTACA-3’ 
MYC:  F: 5’-CCACGTCTCCACACATCAGC-3’ 
R: 5’-CTTGGCAGCAGGATAGTCCTT-3’) 
BCL2:  F: 5’-GTACCTGAACCGGCACCTGC-3’ 
R: 5’-GCAGAGTCTTCAGAGACAGC-3’ 
Claudin 1: F: 5’-TCTTTGACTCCTTGCTGAATCTGA-3’ 
R: 5’-TTGCTATCACTCCCAGGAGGAT-3’ 
APOD:  F: 5’-ATCCAGGCCAACTACTCACT-3’ 
 62 
R: 5’-GATTCACAGTTCCATCAGCT-3’ 
Cathepsin D: F: 5’-AAGCTGTCCCCAGAGGACTACA-3’ 
R: 5’-GGATGTCCATGCCCATGAA-3’ 
CCNA2: F: 5’-TGCAAACTGCAAAGTTGAAA-3’, 
R: 5’-TAAATGAAAGGCAGCTCCAG-3’ 
 
5.3 Results 
5.3.1 Lentiviral expression of ERβ was functional and changed ERα levels in 
MCF7 cells 
We assessed the functional and transcriptional effects of stable ERβ expression in 
two models for the luminal subtype of breast tumors: the human epithelial ERα-
positive breast cancer cell lines: T47D and MCF7 (95,97,98,190). The cell lines 
are derived from ductal carcinoma and adenocarcinoma, respectively, and both 
are dependent on ERα and estrogen for growth. Previous studies have 
characterized the ligand-activated gene regulation by ERα and corresponding 
promotion of cell proliferation and cell survival, along with anti-proliferative 
effect of ER antagonists (191,192). The effects of transient or inducible ERβ 
expression in these cell lines have also been characterized (174,177,178,184).  
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We utilized lentivirus-transduction followed by selection with blasticidin to 
generate T47D and MCF7 cells stably expressing full-length, FLAG-tagged ERβ in 
replicated mixed-cell populations, in duplicates for T47D and triplicates for MCF7 
cells. ERβ transcript and protein levels were significantly increased in the ERβ-
transduced cells compared to the barely detectable levels in parental or control-
transduced cells (Figure 5.1A-B). Competitive ligand-binding assay with tritium-
labeled E2 showed that the T47D-ERβ cells contained more than double as many  
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Figure 5.1 Characterization of ERβ expression in breast cancer cell lines T47D and MCF7. 
Using lentivirus transduction ERβ was expressed in duplicate (T47D) and triplicate (MCF7) mixed-
cell populations. A) ERβ mRNA levels were increased in T47D-ERβ and MCF7-ERβ mixed-cell 
populations compared to in cells transduced with only control vector, as measured by qPCR. ERβ 
mRNA in parental and control cells of both cell lines were barely detectable (CT values>32). B) 
ERβ protein was readily detectable in T47D-ERβ and MCF7-ERβ cells, measured by immunoblot of 
FLAG IP. Cell lysates were subjected to immunoprecipitation (IP) with a FLAG antibody prior to 
blotting with ERβ antibody. The expressed ERβ band is at 1 kDa higher than recombinant ERβ (at 
59 kDa, not shown), due to the 8-aa FLAG tag. FLAG antibody heavy chain is co-eluted and 
crossreacts with secondary antibody, as indicated. IP/WB was carried out in duplicate for each 
mixed-cell population, representative experiment shown. C-D) Radioactive ligand-binding assay 
shows that ligand-binding capacity is enhanced by ERβ expression in both cell lines, and remains 
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high also when ERα is silenced in MCF7 cells. Efficacy of silencing is shown in Figure 5.6C. E) 
Luciferase ERE-transactivation assay in MCF7 cells confirms enhanced transactivation through ERβ 
expression upon E2 treatment. 
 
ligand-binding receptors as the T47D control cells (Figure 5.1C), indicating an 
ERβ-to-ERα ratio of approximately 1:1. MCF7-ERβ also exhibited increased ligand 
binding after expression of ERβ, and siRNA of ERα visualized the contribution by 
ERβ (Figure 5.1D). In MCF7 cells, an ERE-luciferase transactivation assay showed 
that ERβ-expression enhanced transcriptional transactivation from an ERE (Figure 
5.1E). Both receptors are known to form hetero- and homodimers with each 
other, and to co-localize in the cell nuclei of clinical breast tumors and cell lines 
(71). We showed, using co-immunoprecipitation (Co-IP) experiments after vehicle 
and E2 treatment, that ERβ and ERα formed heterodimers in both MCF7-ERβ and 
T47D-ERβ cells, with or without E2 stimuli (Figure 5.2), supporting a previous 
report (193).  
 
ERα has an ERE-containing promoter and can be regulated by both ERs 
(194,195). We assessed whether the levels of ERα changed upon expression of 
ERβ. In T47D cells, the levels of ERα were not affected by neither ERα itself nor 
ERβ, as measured using qPCR and immunoblotting 24 h after vehicle or 10-nM E2 
treatment, in cells with and without ERβ (Figure 5.3A-C). 
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Figure 5.2. ERβ and ERα heterodimerize in T47D and MCF7 cells. Co-IPs using antibodies 
directed against ERα and FLAG (for ERβ) show that the ERs form heterodimers when co-
expressed, both in absence or presence of ligand, in A) T47D and B) MCF7 cells. Co-IPs were 
performed after 24-h treatment with vehicle or 10 nM E2. ERα was detectable in Co-IPs of the 
FLAG-tagged ERβ from both vehicle and E2-treated T47D-ERβ and MCF-ERβ cells. In the control 
cells where ERβ was not expressed, no Co-IP bands were detected, supporting the specificity of the 
experiment. Gels were loaded with equal volumes of input lysate and immunoprecipitate. Light 
and heavy chain (26 and 54 kDa, respectively) of FLAG antibody, FLAG-tagged ERβ at 60 kDa, and 
ERα at 64 kDa are indicated. 
 
In MCF7 cells ERβ expression doubled the basal levels (under estrogen-depleted 
conditions) of ERα (Figure 5.3A, D-E). Although ERα is usually repressed by E2 
treatment, this regulation can vary across experimental conditions and be affected 
by e.g. seeding density of cells and cell synchronization protocols. Small E2-
mediated upregulation of ERα mRNA, as noted in Figure 3A, has been reported in 
MCF7 cells previously (196). ICI treatment promoted degradation of ERα protein 
in all cases, whereas, under the experimental conditions used here, ERα protein 
degradation by E2 was minimal in all cells. We conclude that expression of ERβ 
significantly affected the levels of ERα in MCF7 cells, but not in T47D cells.  
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Figure 5.3 ERβ upregulates ERα in MCF7 but not in T47D cells. A) Relative ERα mRNA levels 
as measured by qPCR in T47D and MCF7 cells after 24 h vehicle and E2 treatment. Bar graphs 
illustrate the average and SD for all mixed-cell populations. B) ERα protein in T47D (left) and 
MCF7 (right) after 24-h treatment with vehicle, 10 nM E2 or 10 nM ICI, Two mixed-cell 
populations were analyzed for each condition and representative experiments are shown. C-E) 
Quantifications of all Western blots are shown for T47D and MCF7, respectively. Band intensities 
were normalized to β-actin. 
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5.3.2 ERβ exerted genome-wide effects on gene regulation and altered 
signaling pathways 
We next examined the effect of ERβ over the transcriptome. Using microarray 
analysis, we assessed changes both at basal level (Control+Veh. vs. ERβ+Veh.) 
and after 24-h estrogen stimulation (Control+E2 vs. ERβ+E2) in biological and 
technical duplicates of both cell lines. The results, illustrated in Figure 5.4A and 
C, indicate that ERβ expression mediated an impact on both basal and E2-
mediated gene expression in both cell lines. A total of 302 genes were regulated 
in both T47D and MCF7 cells (Figure 5.4B and Figure 5.5A), including repression 
of AHR (Aryl hydrocarbon receptor), the Wnt inhibitor DKK1 (Dickkopf 1) and 
TGFB2 (Transforming growth factor beta 2). The repression of both TGFB2 and 
DKK1 indicates potential effects on proliferation (197). Other genes were 
regulated in opposite manner in the two cell lines: The cell-cycle progression and 
poor-prognosis gene CCNA2 (Cyclin A2) (198) was upregulated in MCF7-ERβ but 
downregulated in T47D-ERβ cells and PIK3R1 (p85, a subunit of 
Phosphatidylinositol 3-kinases [PIK3]) that can contribute to non-genomic ERα 
signaling (199,200) was downregulated in MCF7-ERβ but upregulated in T47D-
ERβ cells.  
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Figure 5.4 Large transcriptome effects of ERβ in T47D and MCF7 cells. Microarrays were used 
to analyze changes in gene expression between cells with and without ERβ, in the absence and 
presence of 10 nM E2. Both biological (different mixed-cell populations) and technical replicates 
were used for each condition and cell line. A) A heatmap based on hierarchical clustering of 
transcripts (rows) and samples (columns), illustrates the genome-wide changes of both 
upregulated (red) and downregulated (blue) genes. B) Genes affected by ERβ expression (in 
presence of E2) in both T47D and MCF7 are illustrated using Venn diagram. C) Comparison of 
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genes regulated by ERα (after 24 h of 10-nM E2 treatment) in parental cells with genes affected by 
ERβ expression, is illustrated by a Venn diagram for T47D and MCF7. D) Table showing the 
number of differentially expressed genes under the different conditions, at different cut-off values 
for the fold-change comparison ERβ vs. control cells. 
 
To determine the signaling pathways that were affected by ERβ, we analyzed for 
enrichment of predicted transcription factor (TF) target genes. We found that 
putative targets of E2F and AP-1 were significantly enriched among ERβ-affected 
genes in both cell lines, whereas more Smad3, FoxJ2, and FoxO4 target genes 
were overrepresented in T47D cells and MYC, NFY, and Sp1 target genes 
predominated in MCF7 cells (Table 5.1). ERβ expression resulted in enhanced 
regulation of E2F target genes (data not shown), and although E2F1 is an AP-1 
target gene, many other AP-1 target genes (including APOD, ANXA1, and SYNPO, 
all previously reported as regulated by AP-1 in MCF7 cells (165)) were repressed 
in both cell lines along with the two AP-1 factors c-Fos and c-Jun in MCF7 cells 
(data not shown). In addition, MYC signaling which is imperative in tumor cell 
cycle progression, and regulated by ERα in complex with Nuclear factor-Y (NFY) 
(201), was enhanced along with ERα, and NFY activity (data not shown) in 
MCF7-ERβ cells. 
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Table 5.1. Enrichment of transcription factor target genes in ERβ gene expression profiles.  
Transcription factors whose predicted targets were overrepresented upon expression of ERβ, in the 
presence of E2. N indicates number of genes. The list is ranked according to ascending p-value, 
starting from the top for T47D-ERβ and from the bottom for MCF7-ERβ, and redundant instances 
and motifs for unknown factors are removed. Overrepresentation is considered significant if p < 
0.05, italics indicate no significance. 
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In conclusion, ERβ had major impact on the transcriptome in both cell lines, with 
significant similarities but also cell-specific characteristics. Several known ERα- 
and ERβ-affected transcription factor modules, including AP-1, E2F, MYC, TGFβ, 
NFκB, and FoxO4, were affected as a consequence of ERβ expression in both cell 
lines.  
 
Others and we have previously shown that transient expression of ERβ opposes 
ERα-regulated transcription (174,184). Here, we explored what proportion of 
direct ERα targets were affected by stable ERβ expression. We found that about 
one third of genes that ERβ affected in both cell lines (112 of the 302 genes, 
including TGFB2, PIK3R1 and GATA3) were identified as direct transcriptional 
targets of ERα using GRO-seq analysis (138), as illustrated in Figure 5.5A. 
Further, using microarrays to identify the genes that ERα regulated (24-h E2 
treatment) in each cell line, we compared how ERβ affected these genes. In 
MCF7, 37% of ERα-E2 regulated genes (483 out of 1291, including ERα itself) 
were significantly affected by ERβ expression, whereas in T47D cells only 9% of 
ERα-regulated genes (99 out of 1103 genes) were affected (Figure 5.4C). 
Although the more extensive effects on ERα targets in MCF7-ERβ cells are likely 
attributable to the increase of ERα, ERβ expression appeared to enhance ERα 
signaling for the majority of the affected genes in both cell lines (84% or 406 
genes out of 483 in MCF7, and 75% or 73 out of 97 genes in T47D). ERβ-
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enhanced ERα-target genes included many well-known direct targets (pS2, PR, 
GREB1, MYBL1), and genes involved in functions such as cell proliferation (e.g. 
BCL2, c-Myc, IGFBP4), cell migration/cell adhesion and DNA repair in both cell 
lines (data not shown). ERβ opposed ERα-E2-induction for only 77 genes in 
MCF7-ERβ cells and 24 genes in T47D cells (data not shown). These genes 
include growth- and proliferation-associated TGFB2, SLC3A2, B4GALT1 and 
CCNA2 in T47D-ERβ, and genes associated to cell migration and motion, cell 
death, and hypoxia (e.g. IGF1R, THBS1, KLF10, AEN, CAV1 and PLOD2) in MCF7 
cells. We conclude that while ERβ did attenuate a small proportion of ERα gene-
regulations, this was not its predominant action.  
 
We confirmed the microarray data and dissected the manner in which ERβ 
influences ERα signaling further using qPCR on selected genes. Data for four 
genes where expression of ERβ enhances ERα-E2 regulation, and four genes 
where ERβ expression results in an opposing or divergent E2 response are shown 
in Figure 5.6. The ERE-controlled target gene pS2, the anti-apoptotic BCL2 and 
the proliferative MYC, were increased at both basal and E2-regulated 
transcriptional levels by ERβ in both cell lines. Similarly, ERβ expression 
enhanced the regulation of the proliferative ion-channel KCNK5 (Potassium 
channel, subfamily K, member 5) (129) and the cell-cycle gene CCNA2 (Cyclin 
A2) in MCF7 cells, but attenuated these regulations in T47D cells. ERβ could also  
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Figure 5.5. Overlap between prior genome-wide studies of ER-regulated genes and ours. A) 
Heatmap showing expression of the common set of differentially expressed genes in our study, 
with annotation for genes identified as E2-ERα transcriptional targets previously (138). In B) and 
C) Venn diagrams showing overlap of differentially expressed genes in present study and prior 
studies of gene expression in ERβ-expressing T47D and MCF7 (38,102,202). 
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enhance ERα repression, as illustrated by APOD (Apolipoprotein D) in both cell 
lines. On the other hand, ERβ expression reversed the effect of ERα regulation for 
CLDN1 (Claudin 1), and attenuated the E2-induction of the poor-prognosis gene 
Cathepsin D in both cell lines (all regulations shown in Figure 5). Overall, the 
qPCR analysis confirmed the microarray data and illustrated that ERβ augmented 
ERα-signaling for many critical genes, while mediating differential regulation on 
others. 
 
 
Figure 5.6. Gene-specific transcriptional effects by ERβ. Known ERα-target genes are affected 
by ERβ expression in absence and presence of E2. The regulation of pS2, KCNK5, MYC, BCL2, 
Claudin 1, APOD, Cathepsin D and CCNA2 are illustrated by bar graphs. Statistically significant 
differences between ERβ and non-ERβ expressing cells are indicated by asterisks. The significance 
of changes by E2 treatment alone is not indicated for simplicity. 
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Discriminating the effects of ERα- and ERβ-mediated regulation was complex 
because ERβ upregulated ERα in in MCF7 cells, and E2-treatment downregulated 
ERβ expression in both cell lines (data not shown). We therefor attempted siRNA 
treatment to investigate receptor-specific gene regulations. Silencing of the 
endogenous ERα in MCF7 cells was effective, reducing its mRNA levels by 80-90% 
(Figure 5.7A), and ablating detectable protein expression (Figure 5.7C) along 
with reduction of downstream target genes pS2, CCNA2, and BCL2 (exemplified 
in Figure 5.6D). As ERβ is stably expressed from a CMV promoter, its transcript 
levels could only be mildly reduced by siRNA (by 30% using double transfections, 
Figure 6B). This relatively slight silencing still resulted in reduction of the target 
genes pS2 (Figure 5.7D), CCNA2, and BCL2. Using the ERβ-selective ligand 
KB101471 or E2, in combination with siERα, we demonstrated ERβ homodimer 
transactivation of pS2 (Figure 5.7E). The same experiment in control (no ERβ) 
cells ablated pS2 regulation (Figure 5.7E). Tamoxifen treatment reduced ERβ-
mediated gene regulations (Figure 5.7F). In conclusion, we distinguish gene-
specific effects of both ERs that can be quenched upon silencing of the receptors. 
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Figure 5.7. Receptor-specific effects on gene transcription identified through receptor 
silencing and SERM treatments in MCF7 cells. ER knockdown and ligand treatments with E2 
(10 nM), ERβ-selective ligand KB101471 (0.5 nM) and ER antagonist tamoxifen (1uM) were used 
to identify the contribution by each receptor. qPCR measurements of relative mRNA levels of A) 
ERα and B) ERβ in MCF7-ERβ cells indicate effectiveness of RNA silencing C) Measurements of 
ERα protein levels using Western blot confirm effective ERα silencing in in MCF7-ERβ. D) Both 
ERα and ERβ silencing in MCF7-ERβ cells affect the regulation of direct target gene pS2. E) 
Silencing of ERα and treatment with vehicle, E2 (10 nM) or ERβ-specific agonist KB101471 (0.5 
nM) in MCF7 control and MCF7-ERβ cells reveals ERβ regulation of pS2. F) Similar to E), with 
tamoxifen treatment (1 μM). Panels A, B, and D show average of triplicate experiments. 
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5.3.3 Effect of ERβ expression on genes associated with proliferation, 
apoptosis and adhesion, and respective phenotype 
After establishing that, under the conditions analyzed ERβ enhanced rather than 
attenuated ERα signaling for most target genes, we proceeded to explore the 
biological outcome that stable expression of ERβ generated in these cells. 
Enrichment analyses of gene ontology biological processes, presented in Tables 
5.2 and 5.3, indicated that ERβ affected genes involved in the response to 
estradiol, cell adhesion, apoptosis, proliferation, transcription, and inflammatory 
response in both cell lines. Functional studies were carried out to determine the 
effect of stably expressed ERβ on proliferation, apoptosis, and migration. 
 
To determine the effect of ERβ on cellular proliferation, we subjected cell lines 
grown in full-serum medium for cell counting over a period of 6 to 8 days after 
seeding. T47D-ERβ cells grew at a pace similar to both the control mixes and the 
parental cell line, while MCF7-ERβ cells grew faster than both control and 
parental cells (Figure 5.8A). Thus, ERβ did not exhibit anti-proliferative properties 
when stably expressed in our experiment. 
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Table 5.2. Enriched biological processes in ERβ gene expression profiles. Gene Ontology 
functions that were overrepresented among genes affected by ERβ in both cell lines, in the absence 
of ligand. The list is ranked according to ascending p-value, starting from the top for T47D-ERβ 
and from the bottom for MCF7-ERβ. Redundant terms omitted, N indicates number of genes. 
Overrepresentation is considered significant at p < 0.05. 
 
Next, we evaluated the effect of ERβ under serum-starved conditions, and after 
treatment with E2, tamoxifen or ICI. Using MTS assays, we again observed that 
the expression of ERβ did not significantly change the proliferation of T47D 
(Figure 5.8B). ERβ did, however, slightly reduce the E2-dependent induction of 
cell growth. The growth inhibitory effect of tamoxifen or ICI was similar in the 
ERβ-expressing cells as in the control cells. MCF7-ERβ cells showed an increased 
level of proliferation also in estrogen-depleted media, and an enhanced response 
to E2 (Figure 5.8B). This growth was also reduced by addition of tamoxifen or 
ICI. Control experiments, to verify that control-transduced cells behaved similarly 
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to parental cell lines and to previous experiments using a synchronizing protocol 
(10 nM ICI for 24 h) before E2 treatment, were carried out (Figure 5.8E). The 
effect of ERβ expression on the proliferative phenotype of the two cell lines 
reflected the changes observed at the transcriptome level.  
 
As ERα drives proliferation and the level of ERα was doubled in MCF7-ERβ cells, 
we speculated that this might be the primary driving event for the increased 
growth noted in these cells. We silenced both ERs, and investigated their 
respective impact on proliferation using the MTS assay (Figure 5.8C). Silencing of 
ERα in MCF7-ERβ cells brought down its level to one fifth, yielding 2-fold less 
ERα levels compared to MCF7 control cells. As expected, this silencing 
significantly reversed the increased basal and E2-induced proliferation of the 
MCF7-ERβ cells. ERβ alone could thus not sustain the elevated proliferation. The 
slight silencing of ERβ that we accomplished did not significantly affect 
proliferation. We conclude that ERβ did not mediate anti-proliferative events, and 
that the increased proliferation noted in MCF7-ERβ cells is, at least partly, 
attributed to increased ERα levels. 
 
Both ERα and ERβ have previously been shown to induce, or sensitize different 
type of cells to apoptosis (160,203–208). Apoptosis-associated genes were also 
overrepresented among genes affected by ERβ (Table 5.2). To assess for altered 
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susceptibility to apoptotic events, we examined PARP cleavage in MCF7 cells in 
presence and absence of ERβ, E2, and the DNA-damaging agent cisplatin. We did 
observe increased PARP levels overall by ERβ expression, but the fraction of 
cleaved PARP remained unchanged (data not shown). These experiments, thus, 
did not support an effect on apoptosis in MCF7-ERβ cells.  
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Figure 5.8. ERβ does not repress proliferation in T47D and MCF7 cells. Proliferation was 
measured using both cell counting and MTS assay under varying conditions. A) T47D cells and 
MCF7 cells, with and without ERβ expression, were counted over 6 or 8 days of growth in full-
serum medium. Duplicate (T47D) and triplicate (MCF7) mixed-cell populations were analyzed, 
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and parental MCF7 cells were included. Each measurement was performed in duplicate or 
triplicates, and data for one representative mixed-cell population is shown. Proliferation of B) 
T47D cells and MCF7 cells, with and without ERβ expression, were measured using MTS assay. 
Cells were grown in estrogen-depleted medium and treated with vehicle, 10 nM E2, 10 nM E2+1 
μM tamoxifen or 10 nM E2+1 μM ICI for 3 to 6 days. The average for all mixed-cell populations 
(two for T47D, each repeated twice, three for MCF7, each repeated 4 times) is shown in figure. C) 
Proliferation was measured after silencing of each receptor using MTS assay. Each bar illustrates 
the average for two of the mixed-cell populations, each performed in four replicates and 
measurement made in technical triplicates. D) The influence of ERβ on migration was measured 
using wound-healing assay for T47D and MCF7 cells with and without ERβ, after 24-h E2 (10 nM) 
or vehicle treatment. E) MTS assay to verify that the control cells proliferated similarly to the 
parental cell lines, with treatments as in B). 
 
ERβ has been implicated as a repressor of migration in breast cancer cells (209–
211) and of invasiveness in models of inflammatory breast cancer (212). The 
gene expression profiles of T47D-ERβ and MCF7-ERβ cells suggested altered 
ability of the cells to migrate, as indicated by enrichment of related biological 
processes (Tables 5.3). We performed a wound-healing assay to assess the 
influence of ERα+E2 on migration in control cells, and the corresponding impact 
of ERβ. Our experiments showed that in T47D control cells, E2 treatment 
significantly stimulated ERα-mediated migration (Figure 5.87D), confirming 
previous studies (213). When ERβ was expressed, however, E2 no longer 
mediated a significantly increased migration. This aligns with the observed gene 
regulations in T47D cells where ERβ repressed migratory Claudin 1 expression 
and attenuated the ERα induced TGFβ (TGFB2). In MCF7 cells, on the other hand, 
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migration was not affected by either ERα or ERβ (Figure 7D). The ability of the 
assay to detect effects on migration in MCF7-ERβ cells was, however, occluded by 
increased proliferation under serum-starved conditions upon expression of ERβ. In 
conclusion, ERβ appears to have the capacity to attenuate E2-stimulated 
migration in T47D cells.  
 
Table 5.3. Enriched biological processes among ERβ-regulated genes in both cell lines. 
Overrepresentation analysis based on Gene Ontology gene sets for the common (both MCF7-ERβ 
and T47D-ERβ) differentially expressed genes. N indicates number of genes. Ranking according to 
p-value. 
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5.4 Conclusion 
In this study we aimed to further our understanding of ERβ’s role in ERα-positive 
breast cancer. We generated T47D and MCF7 cell lines co-expressing the two ERs 
constitutively, each in replicated mixed-cell populations. Previous studies have 
indicated that transiently expressed ERβ opposes ERα signaling and 
corresponding proliferative function (as referenced above). After assessing 
constitutive expression at mRNA and protein levels (Figure 5.1), we showed that 
ERβ formed heterodimer with ERα (Figure 5.2) and induced large transcriptomic 
changes in both cell lines (Figure 5.4). Our gene-expression analysis showed that 
general ERα signaling was not attenuated by stably expressed ERβ (Figures 4 and 
5). Enrichment analysis indicated ERβ’s involvement in previously reported 
processes, including proliferation, DNA repair, adhesion, and modulation of the 
inflammatory response (Tables 5.2 and 5.3). Collectively, however, our results 
diverge from the body of data, including our own, that suggests that ERβ in breast 
cancer cell lines opposes ERα gene regulations in a genome-wide manner and 
thereby reduces proliferation.  
 
The enrichment analysis indicated that ERβ-affected genes were involved in 
proliferation, and that key cell-cycle driving genes, including ERα, CCNA2, and 
MYC, were upregulated in MCF7-ERβ cells. Also in T47D-ERβ, proliferative genes 
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were upregulated but a concurrent downregulation of other pro-proliferative 
factors was also observed (e.g. CCNA2). E2F targets were increased in both cell 
lines and the E2F family plays crucial roles in the control of cell cycle and tumor 
progression. The increased E2F activity (data not shown) may be attributed to the 
downregulation of the repressing member, E2F4, in both cell lines. In addition, 
the activating E2F1 was upregulated in MCF7-ERβ cells (data not shown) and the 
repressive E2F7 was upregulated in T47D-ERβ cells, contributing to the more 
extensive effects noted in MCF7 cells. E2F1 is a known target of ERα, regulated in 
tandem with AP-1 in MCF7 cells (165), and constitutes an essential part of ERα-
mediated cellular proliferation of breast cancer cells (165,214,215). AP-1 also has 
a central role in in ERβ-mediated signaling (39,165), and 60% of ERβ-chromatin 
binding sites have been found to contain both ERE- and AP-1-like sites (39). 
Functional analysis demonstrated that ERβ did not affect overall proliferation in 
T47D-ERβ cells, whereas in MCF7-ERβ cells an increased proliferation was 
recorded (Figure 5.8A-B). This was consistently observed in the independent 
mixed-cell populations. We primarily attributed the increased proliferation in 
MCF7 cells to the two-fold increased levels of ERα. Overexpression of ERα in 
MCF7 cells has previously been shown to increase cell proliferation (216,217). 
When we silenced ERα in MCF7-ERβ cells, the cells reduced their proliferation to 
the levels of the control cells. However, since this reduced level of ERα was two-
fold lower than its levels in control or parental cells without corresponding 
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change in proliferation, we cannot exclude that ERβ contributes to a growth 
advantage.  
 
The reasons for the divergent results of ERβ in terms of proliferation can be 
several. We note that most studies concluding anti-proliferative abilities have 
been performed using transient transfection or inducible systems, and we propose 
two factors that may contribute to the divergent results: selection of cells with 
proliferative advantage under stable conditions and/or cofactor squelching during 
transient conditions. The selection of stably expressing ERβ cells could enrich for 
cells that can proliferate in the presence of ERβ, thereby obscuring anti-
proliferative properties. We initially noted, within a week of transduction, that 
ERβ opposed ERα signaling in the T47D-ERβ cells, as reported previously (184). 
However, as the cells adapted to ERβ expression this was reverted to a pro-ERα 
activity for many target genes in both T47D and MCF7 cells. It is possible that the 
selection favors cells that can proliferate in the presence of ERβ in a non-
physiological manner. However, the fact that we observed the same results in 
each of the mixed-cell populations analyzed, and did not note an anti-proliferative 
effect in either cell population, indicates that this is not an infrequent 
characteristic. Possibly, similar characteristics may evolve in clinical tumors. As 
we have used the same system and selection procedure and found ERβ to be anti-
proliferative in colon cancer cells (182,204), we know that this approach can be 
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used to detect anti-proliferative functions of ERβ. We need to also consider the 
impact of cofactor squelching during transient expression (218). When significant 
levels of ERβ are introduced, ERβ will compete for interaction with many of the 
same cofactors that ERα also requires. This, by itself, can result in an attenuation 
of the ERα-mediated gene regulation and proliferation. When ERβ is stably 
expressed, on the other hand, the cells can adapt and reach a steady-state level of 
needed factors. Cells with stable expression may therefore evade the squelching 
effect. Our result that ERβ is not anti-proliferative when stably expressed in breast 
cancer cells aligns with clinical findings where ERβ in vivo often does not 
correlate with an anti-proliferative phenotype (as referenced in introduction and 
reviewed by Leygue and Murphy (79)). Although analysis of stable ERβ 
expression in MCF7 cells was recently reported (38,202) and a reduced 
proliferative response to E2 was noted (38), effects on basal proliferation or 
interplay with ERα were not explored in detail. In triple-negative breast cancer 
cell lines, several studies have reported a lack of anti-proliferative effects by ERβ 
(219–221). We suggest that our study offers a potential mechanistic model for 
ERβ’s role in a subset of breast tumors. Our result does not preclude that ERβ can 
posses anti-proliferative abilities in other cells, in other circumstances, or when 
activated de novo.  
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Aligning with our results that stably expressed ERβ did not reduce proliferation in 
ERα-positive breast cancer cells, we did not observe extensive attenuation of 
ERα’s transcriptional regulation in our experiments. On the contrary, we noted an 
enhancement of ERα target gene regulation when ERβ was expressed in both cell 
lines (Figure 5). It is established that homo- and heterodimers of both ERs bind at 
the promoter of e.g. pS2 (38,39,222,223), but conflicting data have been reported 
as to whether ERβ opposes or enhances ERα’s regulation (38,184,202,222,223). 
Our data indicate that ERβ enhances the ERα-E2 response for most co-regulated 
genes, in both cell lines. Of note is that ERα levels were induced 2-fold by ERβ in 
MCF7 cells, which contributed to an enhanced E2 response in these cells. ERα 
regulation was however attenuated by ERβ for a small proportion of target genes 
in both cell lines (Figure 5.5). In T47D cells, further, the ERα levels were 
unchanged, but the regulations of known ERα-targets were still enhanced. Our 
data align with a previous suggestion that the ERα-ERβ heterodimer largely acts 
in a manner similar to the ERα homodimer (224). It is likely that the type of 
regulation depends on whether ERβ binds as homo- or heterodimer, and whether 
it binds to cis-regulatory sequences at ERE sites or tethers with AP-1 or Sp1 
transcription modules.  
 
Three groups have compared the DNA-binding sites of both receptors in MCF7 
cells at a genomic scale (38–40). They found that 33-73% of ERβ-binding sites 
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were sites where ERα homodimer can also bind, and that the majority of binding 
sites contained full or half EREs. Zhao et al. found significant enrichment of AP-1 
and Forkhead motifs, and that 60% of ERβ-binding sites contained both ERE- and 
AP-1-like sites (39). Thus, the two ERs can bind many common regions that 
possibly are dominated by full EREs, whereas sites unique to each ER might be 
enriched for other type of motifs. ERα is known to activate AP-1 sites (165), 
whereas ERβ has been reported both to repress (225) and activate (226) such 
transcription. Our data support that AP-1 targets, with E2F1 as one exception, 
were repressed by ERβ. Further, we note that genes with Sp1 motifs in their 
promoters were upregulated in MCF7-ERβ cells, correlating with findings of ERβ 
activity in osteosarcoma cell line U2OS (227). That one of the few genes where 
ERβ opposed ERα in both cell lines, Cathepsin D, is regulated in complex with Sp1 
(228–230) , may indicate that ERβ’s influence on ERα-mediated regulation via 
Sp1 tethering is different from that of direct regulation. Global ChIP-reChIP would 
need to be carried out to fully characterize genomic binding of the ER 
heterodimer, and to differentiate it from common binding by ERα and ERβ 
homodimers.  
 
We compared our gene expression dataset to the recently published data from 
MCF7 cells also engineered to express ERβ stably (38,202) as well as our previous 
study of inducible ERβ expression in T47D cells (184). Whereas the overlap of 
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transcriptional changes between transient and stable ERβ expression in T47D cells 
was low (10% of the transient-ERβ regulated genes were observed), comparison 
between studies of stable expression in MCF7 cells rendered a relatively large 
overlap. Here, 37% and 34%, respectively, of genes previously identified as 
regulated by ERβ expression were changed in our study (data not shown), 
supporting the generality of these data 
 
We further observed that E2-induced migration was opposed in T47D cells, that 
the MCF7-ERβ-expressing cells adhered to each other more strongly than the 
control cells, and that migration and proliferation assays was more dependent on 
cellular confluency when the cells expressed ERβ. ERβ also affected several cell-
adhesion genes in both cell lines, including repression of TGFB2 and, in MCF7-
ERβ cells, repression of the TGFβ-induced KLF10, which has been demonstrated 
as an ERβ-specific target in U2OS cells (231). These properties are in line with 
evidence that ERβ has a role in cellular adhesion and TGFβ signaling 
(174,210,211,232). Due to the dual roles of TGFβ in cellular proliferation, cellular 
migration and cancer metastasis (233–236), this aspect of ERβ regulation merits 
further investigation.  
 
Our study suggests that ERα signaling and estrogen-induced proliferation can be 
unaffected or enhanced by ERβ, and that tamoxifen or ICI treatment is still able to 
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block these functions (Figure 5.). In addition, the previously described 
upregulation of SPINK4 by tamoxifen-liganded ERα (237) was maintained or 
enhanced in the presence of ERβ in both cell lines (data not shown). Several 
studies have concluded that tamoxifen is an antagonist to ERβ (238), but other 
has suggested that ERα-positive tumor cells become resistant to tamoxifen when 
ERβ is expressed (239). Our data support that patients with ERα/ERβ-positive 
tumors may benefit from tamoxifen or fulvestrant treatment, in line with the 
clinical evidence presented by Honma et al. (65).  
 
In conclusion, we present evidence that breast cancer cells are able to continue 
proliferating and thrive while stably expressing significant levels of ERβ. Our 
analysis shows that ERβ can enhance rather than oppose ERα-signaling, and this 
knowledge aids in the understanding of the role ERβ mediates in some ERα/ERβ-
positive breast cancer cells. Our study supports that the better survival noted in 
tamoxifen-treated patients with ERβ-positive tumors is because tamoxifen 
antagonizes both ERα and ERβ signaling. However, as also beneficial functions 
appeared mediated by ERβ, e.g. repression of Cathepsin D and migration, the 
optimal treatment approach will need to be carefully evaluated. In vivo studies are 
needed to investigate how stable ERβ expression impacts tumor metastasis in 
ERα-positive breast cancer cells. As ERβ is a highly druggable target, a better 
understanding of its function is critical. Currently, only ERα is utilized in the clinic 
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and our study supports the accumulating data that ERβ is a promising target for 
breast cancer therapy. 
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6.  Concluding remarks and future directions 
The estrogen receptors are of high interest for their pivotal role in many biological 
processes, as well as their involvement in multiple human diseases. As 
transcription factors the control large transcriptional programs, the effect upon 
which is modulated by a plethora of factors. Such factors include the presence of 
receptor ligands of various specificity and potency, coregulatory proteins that 
interact with the ERs at the DNA, as well as proteins from other signal 
transduction pathway that crosstalk with the ERs. Collectively, this makes the ER 
signaling a complex system to dissect.  
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In order to study the signaling of the ERs in breast cancer, and the pathways by 
which they regulate oncogenic processes, we utilize immortalized cell lines, which 
allows for manipulations of various kinds, in order to understand this biology.  
 
In chapter one, we describe how ERα directly regulates the expression of the ion 
channel KCNK5, and how this ion channel is involved in cell proliferation. 
Silencing the KCNK5’s expression reduced basal and E2-induced proliferation. 
This discovery suggests that ion channels, as ER targets, are potential proliferative 
factors and thus also potential therapeutic targets. Further studies are required to 
elucidate whether KCNK5, or other ion channels, are under ER control in human 
breast tumors, and, if so, whether the blocking of the channel has any beneficial 
effect for the patient. 
 
The second chapter describes our effort to extend out knowledge of the 
transcriptional program that ERα controls in breast cancer cells. Until recently, 
most studies of this kind have been biased, in the sense that they only have 
interrogated the known, protein-coding transcriptome. RNA-seq, which we 
applied here, allows for an unbiased view of all or a select subset of RNAs. In our 
study we observed the commonplace ERα–mediated regulation of protein-coding 
genes, but more interestingly, the regulation of lncRNAs (and pseudogenes). How 
lncRNAs function and what roles they have in human biology, is still a field in its 
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infancy, and only approximately one percent of bona fide or computationally 
predicted lncRNAs have experimentally been ascribed a function. To extend upon 
our research, the regulation of individual lncRNAs should be verified and their 
possibly role in tumorigenic processes in breast cancer assessed. Additionally, 
studies should also, albeit technically challenging, focus on the whole 
transcriptome to uncover other transcriptional targets of ERα, as well as other 
aspects of transcriptional regulation such as alternative splicing and allele-specific 
expression. 
 
Finally, the third chapter revolves around ERβ. Studies of ERβ are hampered by 
its elusive expression pattern, the paradoxical findings of its near-absence of 
mRNA yet presence of protein, and the lack of specific and commercially available 
antibodies. The lion’s share of studies of ERβ’s function in breast cancer point to it 
being an anti-proliferative factor that possible counteracts the adverse effects of 
ERα. However, clinical data remain inconclusive and contradictory on this topic, 
and no ERβ-targeted therapy is available for breast cancer. If ERβ is expressed at 
the levels it has been demonstrated to be, in breast tumors, it would make it a 
unique tumor suppressor to be so ubiquitously expressed in tumors. In our study, 
we find that long-term established stable cell lines expressing ERβ do, in fact, 
suggest that the receptor not always counteracts the effects of ERα, not on 
regulation of individual genes, nor on the cell proliferation. Much remains to be 
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done in order to develop our understanding of ERβs function, in normal as well as 
disease biology.  
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